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Abstract 
Evaluation of Non-target Analyses of Novel Psychoactive Substances; Inherent Variation in 
GCMS Relative Abundances and Gas Phase Hydrogen Deuterium Exchange Isomer 
Discrimination 
 
Kristin Michelle Kelly 
 
Novel psychoactive substances (NPSs) are synthetically derived compounds designed to 
mimic the effects of other illicit drugs. An endless cycle of NPSs continually reach the drug 
market due to limitations in drug legislation creating two problems: (1) non-availability of 
standards and (2) multiple isobars indistinguishable even to high resolution mass spectrometry. 
Gas chromatography-mass spectrometry (GCMS) is the most common instrument used for 
compound identification in non-targeted seized drug analysis. Compound identification using 
this technique relies on mass spectra where the percent relative abundances (%RAs) of all m/z 
values are compared manually or searched against a library database. Lacking standards, 
laboratories rely on published GCMS spectra to postulate compound identification. The ability to 
make such identifications provides vital investigative data and may help uncover new structural 
variants. However, central to such identifications is an understanding of how much spectral 
patterns vary across laboratories; the assumption that variation is minimized through the use of a 
standard tuning compound perfluorotributylphosphine (PFTBA) has yet to be rigorously tested 
and demonstrated. The first focus of this research was the often-unappreciated aspect to any 
mass spectral comparison or search- the inherent variation in RAs. 
 
In the first study, the variation of mass spectral fragmentation patterns characterized by 
%RA was evaluated using three GCMS instruments and 16 NPS compounds. The variation of 
retention indices was also studied. Retention indices showed <0.35% variation across all 
systems; mass spectral data showed much greater variation across all compounds and systems. 
Tuning frequency was one factor correlated with a small, but significant, effect on the variance. 
A t-test comparison of mean ion %RA did not clearly identify general patterns. The identity of 
the base peak changed for three compounds. Alternating base peaks on a single instrument, i.e. 
one instrument produced multiple base peak ions over the course of the study, generated a ripple 
effect, where variation across all %RAs in the effected spectra increased. However, alternating 
base peaks between instrument, i.e. each instrument produced a single base peak but the ion 
identity was not necessarily the same, did not produce these ripple effects. The variance in %RA 
caused by alternating base peaks has the potential to skew compound identification during non-
targeted analyses, which are common in a forensic drug chemistry setting. 
 
 Decades ago, the Environmental Protection Agency (EPA) established tune check 
compounds as a means to control systematic variation across vendor platforms, which was the 
focus of the second study. The goal of the second study was to evaluate whether the 
decafluorotriphenylphosphine (DFTPP) criteria, as defined by the EPA, could be used to reduce 
the RA variation in mass spectra produced by NPSs. Instruments from two vendors were used to 
analyze 6 NPSs: 4 cannabinoids and 2 cathinones. Each NPS was analyzed 100 times per 
instrument; 10 replicates per tune repeated under 10 different tunes. Results showed that passing 
a DFTPP tune check was not correlated with reduced RA variation. Tuning algorithm differences 
 
 
between vendors did impact the %RA variance, but the frequency of instrument tuning was 
found to be the most critical factor for controlling RA variation. The results of this work suggest 
that forensic laboratories should develop quantitative metrics to evaluate autotuning results and 
define how these metrics will be used to dictate maintenance. This practice, coupled with tuning 
before each analytical batch, will reduce the variation of %RA values as much as practicable. 
 
Because GCMS usually cannot distinguish constitutional isomers, the second focus of 
this research was to develop a novel methodology for the NPS isomer discrimination. Ion 
mobility spectrometry-mass spectrometry (IMS-MS) is used as a non-confirmatory screening 
technique for illicit substances in high traffic areas. Through the years, advancements in 
instrumentation have improved detection limits, increased resolving power, and allowed for 
unique instrument modifications which improve structural inferences. Gas-phase hydrogen 
deuterium exchange (HDX) is one such modification technique. HDX-IMS-MS has been used 
primarily for proteomic and metabolomic applications, but it is also effective in discriminating of 
small biomolecules (glycan linkages). 
 
For the final study, NPSs containing labile heteroatom hydrogens were evaluated for 
HDX reactivity in the presence of either deuterated water (D2O) or ammonia (ND3) within the 
drift tube. An initial evaluation of exchange propensity was performed for six NPSs. Five of the 
initial NPSs exchanged in the presence of ND3, while only one NPS (benzyl piperazine) 
exchanged with D2O. The exchange mechanism of D2O requires stabilization with a nearby 
charged site; the diamine ring of benzyl piperazine provided this charge site at a fixed length. 
Three disubstituted benzene isomers (ortho-, meta-, and para-) containing the diamine ring 
structure and a fluorine atom were analyzed to determine if isomer discrimination was possible. 
These isomers had nearly identical collisional cross sections and isotopic distributions in the drift 
gas, therefore IMS and MS alone cannot discriminate between the isomers. A t-test of means 
(α=0.05) showed that discrimination was possible if the exchange data from both reagent gases 
were included. Molecular dynamics simulations showed that the proximity of the fluorine to the 
diamine ring hinders the dihedral angle between the benzene ring and the diamine ring. The 
angle limitation partially accounts the observed exchange differences. One clear limitation of this 
technique is that the substance must exchange in the presence of both reagent gases. 
Nevertheless, this technique was shown to be capable of isomer discrimination in non-targeted 
analyses of NPSs
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N,N-Dimethyltryptamine…………………………………………3-(2-dimethylaminoethyl)indole 
N-Ethylbuphedrone….……...………………………………2-(Ethylamino)-1-phenylbutan-1-one 
Ortho-fluorophenyl piperazine………………………………………1-(2-fluorophenyl)piperazine 
Para-fluorophenyl piperazine………………………………………..1-(4-fluorophenyl)piperazine 
UR-144……………… ……(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
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Chapter 1: Introduction 
1.1 Background Information 
1.1.1 Definition of Novel Psychoactive Substances 
Novel psychoactive substances (NPSs) are a family of synthetically derived compounds 
designed to mimic the effects of other illicit drugs. By United Nations Office on Drugs and 
Crime (UNODC) definition, these are psychoactive compounds, either pure or in prepared 
mixtures, that pose a similar public health concern as controlled substances but themselves are 
not under current legislation. The term ‘novel’ directly refers to availability for abuse and misuse 
but not necessarily to first synthesis.1-2 Herein, NPSs will refer to both substances which 
currently fit this definition as well as substances which previously fit the definition. 
Numerous terms have previously been used to describe NPSs including designer drugs 
and legal highs. Although all three terms are interrelated there are subtle differences in the 
definitions established by international agencies. Designer drugs are substances specifically 
manufactured to escape existing drug control measures on national and/or international levels. 
These substances are structural derivatives of a parent compound and mimic the pharmacological 
behavior. On the other hand, legal highs refer to psychoactive substances escaping drug control 
measures in the country which they are sold. Legal high substances are designed to mimic 
behavior of a specific compound with or without structural similarity. The term NPSs, defined 
above, was established to streamline policy making and includes both designer drugs and legal 
highs.1 
NPSs can be analogues or mimetics. An analogue is a structural derivative of a parent 
compound usually containing small side chain substitutions. Importantly, analogues may or may 
not have similar pharmacological properties as the parent compound. On the other hand, 
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mimetics are structurally different but mimic the pharmacological activity of a particular 
substance by acting on the same the same receptor.1 NPSs are also classified into categories, also 
known as groups, and families within each category. Categories refer to a collection of mimetic 
compounds related to a specific regulated substance; each category can contain multiple families. 
NPS families are analogues with side chain substitutions or structural rearrangements that have 
varying effects on pharmacological activity. Because the backbone or base structure of families 
are nearly identical, structural isomers and isobaric compounds have been identified, and, as 
described below, this can make identification challenging. 
There are seven NPS categories defined by the UNODC; the two largest categories are 
synthetic cannabinoids and cathinones1-8, these are described in more detail below. Other 
categories include phenethylamines, piperazines, ketamine, plant-based substances, and 
miscellaneous.2 Alternative groupings (including opioid-like drugs, tryptamines, and 
aminoindanes) have been proposed in literature to further classify the wide-range of compounds 
which fall under the miscellaneous umbrella term.1, 4-5, 9-10  
Synthetic cannabinoids or cannabimimetics are the most prolific category containing 
approximately 14 different families.1, 4-7 This category of substances interacts with CB1 and CB2 
cannabinoid receptors and mimic the effects of 9-tetrahydrocannbinol, the primary active 
compound in cannabis.6 Synthetic cathinones, or bath salts, are -ketoamphetamines which are 
structurally similar and mimic the effects of amphetamines, methylenedioxymethamphetamine 
(MDMA), and cocaine. These NPSs are derivatives of cathinone, the active compound extracted 
from the Khat plant (Catha edulis). 4, 8, 11 Two distinct groups exist within this category, semi-
synthetic and synthetic, which are cathinone derivatives and MDMA-like lab created 
compounds, respectively.8 
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1.1.2 Relevant Legislation 
NPSs fall outside of the international drug control system and are therefore not included in 
neither the 1961 Convention nor the 1971 Convention.3 Despite the Expert Committee on Drug 
Dependence of the World Health Organization reviewing several NPSs, these compounds in 
large have not been adopted into the current international scheduling agreements.3 As a result, 
regions and individual nations have adopted legislation to address the growing epidemic. Of 
particular relevance to this work is the United States (US) which adopted the Controlled 
Substances Act of 1970.12 This act uses various factors in order to categorize substances into five 
groups, termed schedules.12 According to subsection (h) of the act, substances can be temporarily 
scheduled for 2 years as a means of avoiding imminent public health safety.12 However, the 
Controlled Substances Act defines substances by the unique and specific molecular structure of 
the compound. 
Because the US drug regulations are largely limited by chemical structure of the active 
substance or substances, the small side chain substitutions of NPS families allow newly available 
analogues to evade drug regulations at the time they are released to the drug market.1, 4-5, 7 In an 
attempt to prevent this creative circumvention of the Controlled Substances Act, the US enacted 
the Anti-drug Abuse Act of 1986.13 This act effectively extended drug legislation of specific 
drug schedules to analogues so long as the compound is marketed for human consumption.13 
However, NPSs are marketed worldwide as research chemicals, air fresheners, plant food, and 
bath salts. Disclaimers are also often present on packaging labels, such as ‘not for human 
consumption’ and ‘for research purposes only’. It is these labels and disclaimers that aide NPSs 
to temporarily circumvent not only the updated US drug legislation, but the legislation of 
countries worldwide.4-5 
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1.1.3 Prevalence of Use 
Two studies, described in detail below, examined whether the national scheduling of 
NPSs was effective at deterring the overall interest in these illicit drugs and whether legislation 
was effective in preventing the sale of the scheduled substances. 
In 2015 Ledberg14 analyzed Swedish online forum chatter from over 3800 websites and 
3,700 individual users. These websites were separated into eight different threads, one for each 
specific NPS studied. Using a time-series model, the activity levels on each thread were studied 
for correlation between intensity of activity, defined as the posts per day, and the date of 
substance regulation, determined to be the 180 days before and the 180 days after scheduling 
occurred. For seven of the eight NPSs, there was a strong statistical association between the legal 
status and activity relating to the substance; as the legal status changed there was a statistically 
significant reduction in online activity mentioning the substance. The last substance showed a 
statistically significant reduction in activity when the time-series window was doubled. Also 
investigated was whether the reduction in activity was due to members losing general interest in 
drugs or whether the members were turning to other drug forums to continue their online 
activity. The activity of a random subset of users was followed for the 180-day time-series 
window from five of the study’s threads. For three of the five investigated NPS threads, the 
selected member’s online activity was diverted to another thread; this indicated that while the 
interest in the particular NPS decreased after the legal status change, the general interest in NPSs 
did not.14 Although this study was conducted specifically focusing on Swedish online forums, it 
shows that a likely scenario is the diversion of interest from a newly scheduled substance to a 
replacement. Furthermore, the author indicates that although this data shows correlation it does 
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not speak to causation; meaning that the reduction in online discussion activity could be the 
result of the product being removed from circulation in head shops or online distributors.14 
Belackova et. al15 studied whether the online accessibility and availability of select NPSs 
changed after controlling laws were enacted in five European countries.15 The authors defined 
accessibility as the number of unique e-shops identified as selling the specific substance per 
country; whereas availability was defined as whether or not the e-shop was stocked and shipping 
the substance to the each of the countries at two specific time points. The first time point was 
chosen to be shortly before the risk assessment of the NPSs of interest was released by the 
European Monitoring Centre for Drugs and Drug Addiction in 2014, while the second was in late 
2015 shortly after the control measures were adopted by the European Union states for the 
compounds of interest. From the first to second time point the number of e-shops selling at least 
one of the four NPSs decreased by half, 33 e-shops after control compared to 66 before the risk 
assessment. Only nine shops were identified in both sample sets. This means that 57 e-shops 
ceased to exist, no longer sold any products, or did not offer the NPSs of interest and 24 new e-
shops selling the controlled substances appeared. Despite the appearance of new e-shops, the 
overall accessibility of the compounds of interest decreased, but the changes in the availability 
were compound and country specific. For instance, the authors noted an increase in the 
availability of AH-7921 in France and Poland after the control measures were adopted compared 
to before. With the exception of 25I-NBOMe in the Netherlands, all compounds available in 
2014 were still available in 2015; the authors suggest this is evidence to the ineffectiveness of 
country specific legislation.15 
Together these studies indicate that while the packaging loophole is being exploited, the 
enacting of legislation to control individual compounds may not be effective in managing, or 
6 
 
even slowing, the NPS epidemic. In a seemingly never-ending cycle, once a newly characterized 
NPS is scheduled, an alternative, unscheduled analogue can act as a replacement but the original 
NPS may still be available on the market. This in sum creates a unique problem for forensic 
scientists- whether the substance being tested is a new, uncharacterized NPS; whether the 
substance has been characterized but is not controlled by drug regulations; or whether the NPS is 
unidentified, uncharacterized, and new to the drug market. Forensic scientists are now tasked 
with distinguishing between structural isomers and isobars in order to determine the legal status 
of the compound; therefore, analytical detection and characterization methods as well as the 
uncertainty behind each technique used are more important now than historically in forensic drug 
chemistry. 
1.2 Instrumentation 
1.2.1 ASTM Analysis Standard 
A UNODC survey from 60 countries and territories showed the most often used method 
for identification of NPSs was chemical analysis techniques, including gas chromatography-mass 
spectrometry (GCMS) and ion mobility spectrometry (IMS); the second was the use of reference 
standards.3  The American Society for Testing and Materials Int. (ASTM) defines the minimum 
criteria for qualitative identification of seized drugs in ASTM E2329-17.16 In this standard 
practice, the analytical techniques are categorized into three groups (A, B, and C) based on 
maximum potential to discriminate between drug compounds, where category A has the highest 
discrimination power. By definition, when a category A technique is used a second and different 
technique, from A, B, or C, must also be employed. If a category A technique is not used, then 
three different techniques at least two from category B must be used. Hyphenated techniques, i.e. 
GCMS and IMS-MS, are considered two separate techniques, where GC and IMS are category B 
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and MS is a category A; therefore, these techniques meet the ASTM discrimination criteria. This 
definition is in agreement with the recommendations set forth by the Scientific Working Group 
on the Analysis of Seized Drugs (SWGDRUG).17 Additionally, SWGDRUG recommendations 
acknowledge that the discrimination power of any technique may be lower than the classification 
if the sample, analyte, or mode of operation hinders the data’s discrimination. One example 
provided by SWGDRUG would be a MS technique that only provides molecular weight 
information.17 
1.2.2 Gas Chromatography Mass Spectrometry 
A basic schematic of GCMS instrumentation is shown in Figure 1.1. A liquid sample, 
consisting of the analyte(s) of interest dissolved in an organic solvent, is injected into the 
injection port and is near instantaneously vaporized. An inert gaseous mobile phase is used to 
move the analytes through a capillary column located within an oven. Separation is the result of 
the analytes partitioning between gaseous mobile phase and stationary phase in the column. 
Temperature programing is used to improve separation by the slow and controlled oven 
temperature increase. Compounds with similar boiling points will have different rates of 
vaporization/condensation creating a larger separation between compounds.18 The retention time 
refers to the time at which compounds elute from the column into the mass spectrometer.  
 
Figure 1.1. Schematic of GCMS instrumentation. 
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The most common type of mass spectrometer coupled to GC is a quadrupole mass filter 
capable of both electron impact (EI) and chemical ionization. In electron impact ionization, an 
energetic electron collides with a neutral molecule transferring kinetic energy.19 An effective 
collision leaves the once neutral molecule as a positively charged ion; the ion will fragment 
when the internal energy of the cation exceeds the dissociation energy level. A quadrupole mass 
filter separates the fragment ions by creating an oscillating electric field between four rods. Ions 
of the correct mass-to-charge (m/z) value maintain a stable trajectory and enter the detector, 
while all other m/z values experience an unstable trajectory and are ejected from the mass filter. 
A user specified range of m/z values is scanned repeatedly, producing a mass spectrum 
containing all the fragment ions and, when present, the parent ion.19 The signal intensity of a 
mass spectra is displayed in terms of percent relative abundance (%RA), where the intensity of 
all ions is scaled to the most intense ion signal detected.  
GCMS analyses produce two types of data that can be used to identify unknown analytes 
of interest: a chromatogram showing the retention time and a mass spectrum. Retention times 
cannot be compared across all methods because the time of elution is temperature dependent. A 
value known as retention index (RI) was developed in order to compare data between methods. 
The mass spectra of analytes are either compared manually against mass spectra from certified 
reference material, also known as a standard, or a mass spectral library search is performed. 
1.2.3 Ion Mobility Spectrometry Mass Spectrometry 
A basic schematic of a drift tube IMS-MS is shown in Figure 1.2. Although many 
ionization sources can be used, of relevance to this work is electrospray ionization (ESI). The 
liquid sample solution (containing the analytes, organic solvent, and dilute organic acid) is 
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aerosolized through a spray capillary carrying a potential. The aerosol consisting of μm sized 
charged droplets expands into a heated desolvation region and undergoes vaporization. 
Vaporization is the result of repetitive shrinking and droplet disintegration through either the 
charge-residue model or the ion evaporation model. Although each model has sufficient 
supporting evidence, it is widely accepted that small molecule ion formation is best described by 
the ion evaporation model, where the analyte of interest evaporates directly from the highly 
charged droplet surface. 19  
 
Figure 1.2. Schematic of IMS-MS instrumentation. 
 
 Ions are then periodically pulsed into the drift tube. Ring electrodes accelerate ions 
through the drift region while a neutral carrier gas flows opposite to the analytes. Larger, 
elongated molecules are slowed by more frequent collisions with the carrier gas, while smaller, 
compact molecules experience fewer collisions. Thus, separation is based on a molecule’s size-
to-charge ratio. Although a multitude of mass spectrometers can be coupled to IMS, the linear 
ion trap is relevant to this work. When the front and back trapping plates have a low and high 
potential, respectively, the ions are allowed to enter the quadrupole; the front potential is quickly 
increased thereby trapping the ions between the two plates. Similar to the description above, the 
quadrupole filters ions for specific m/z values. The potential of the back-trapping plate is lowered 
and ions of the selected m/z values exit into the octupole and are detected.  
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 IMS-MS analyses produce two types of data that can be used to identify unknown 
analytes of interest. The drift time, or the time it takes for an analyte to traverse the drift tube, 
can be used to calculate the ion mobility (K). An ion mobility (Equation 1.1) is the 
proportionality factor between the ion’s velocity and the electric field strength; however, this 
value is dependent on experimental conditions and cannot be compared between instruments.  
𝐾 =
𝑉𝐷
𝐸
           eq. 1.1 
where K is the ion mobility, E is the electric field strength, and VD is the average velocity of a 
drifting ion. Using the Mason-Schamp equation (Equation 1.2) the collisional cross section 
(CCS), or the mean of the collision area between the analyte of interest among all orientations 
and the neutral drift gas, can be found. It is important to note that K and CCS cannot be 
compared between different drift gases. 
𝛺 =
𝑧𝑒
16𝑁
√
18𝜋
𝑘𝐵𝑇
√
1
𝑚𝑖
+
1
𝑚𝐵
𝑡𝐷𝑇𝑎𝐸×760
𝐿𝑃×273.2
        eq. 1.2 
where Ω is the CCS, ze is the ion charge, N is the number density of the buffer gas, kB is 
Boltzmann’s constant, Ta is the absolute temperature, mB is the reduced mass of the buffer gas, M 
is the reduced mass of the ions of interest, L is the length of the drift tube, T is the temperature of 
the drift gas, P is the pressure of the drift gas, E is the electric field, and tD is the drift time of the 
analyte of interest. The second type of data which can be used for identification is mass spectra, 
similar to those described earlier. The mass spectra produced by a linear ion trap generally 
contain the molecular ion peak, frequently not present in EI spectra, and can contain fewer 
fragmentation peaks due to the different ionization techniques. 
1.2.4 Hydrogen Deuterium Exchange 
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Hydrogen deuterium exchange (HDX) describes reactions in which a labile hydrogen(s) 
on an analyte are replaced with deuteron(s) resulting in neutron mass gain.20 Although it is 
possible to exchange carbon bonded hydrogens, labile hydrogens are most often bonded to 
heteroatoms as they are generally more acidic and therefore more easily replaced.20 HDX has 
been employed to magnify the structural information obtained during IMS analyses. It is been 
used both as a sample preparation technique, involving liquid phase reactions, and as an on-line 
technique where gas phase reactions occur within the instrument or during ionization.20-21 Liquid 
phase HDX has historically been used in drug discovery applications, namely for determining 
protein structural changes22-23; however, the use of this technique in complex mixture analysis is 
limited. Gas phase HDX, on the other hand, has recently been used to distinguish biomolecule 
isomers and conformation populations in complex mixture analyses.21, 24-26 Of particular interest 
is work by Uppal et. al24 in which IMS-MS alone was unable to resolve several of the mono- and 
oligo- saccharides studied.24 The gas phase HDX rate was reported to be sufficiently distinct and 
capable of distinguishing glycan ions and linkage isomers.24 Additionally, fragment ions, 
regardless of the starting carbohydrate structure, could be distinguished and identified by the rate 
of deuteron uptake. Because NPSs are small compared to many proteins and peptides studied via 
HDX and IMS, Uppal et. al’s24 work highlights that this technique is capable of distinguishing 
small biomolecules with minor differences. This, in turn, suggests that HDX has the potential to 
distinguish small synthetic molecules such as NPSs.  
Gas phase HDX reaction mechanisms of various deuterated reagents were studied and 
proposed in the 1990’s by Beauchamp et. al.27 Relevant to the work presented here, are the 
suggested reaction mechanisms for deuterated water and ammonia, D2O and ND3. Because the 
exchange mechanisms are different, the structural information which can be elucidated by 
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analysis in the presence of each reagent is also different. It is therefore important to analyze each 
analyte with each reagent gas. 
It was suggested that HDX involving D2O occurs via the ‘relay mechanism’. Here, the 
hydrogen from the protonation site is transferred to the deuterated reagent molecule as the 
deuteron is shuttled to a less basic site on the analyte. Importantly, a charged shuttle molecule or 
additional chargeable site on the analyte must be in close proximity to the protonation site in 
order to balance the charges during the deuteron transfer. This proposed mechanism reflects the 
proton affinity of D2O, which is too low to overcome the endothermicity of the exchange, and 
requires a long-lived intermediate reaction complex, involving the analyte, shuttle molecule, and 
deuterated water, to be formed. It was also noted that, due to the low proton affinity and long-
lived reaction complex, exchanges occurring with D2O are likely more discriminate, wherein not 
all labile hydrogens will undergo exchange.  
Exchanges involving ND3 were proposed to occur via the ‘onium ion mechanism’. This 
mechanism requires the simultaneous solvation of the onium ion as the deuteron is exchanged 
with a proton on the basic exchange site. Exchanges via the onium mechanism can only occur if 
the energy recovered from solvation is greater than the energy lost by the exchange.  Accounting 
for this, the proposed exchange is considered nominally endothermic and comparatively faster by 
the authors. It was, therefore, suggested to be less discriminate and all labile hydrogens are 
exchanged on the analyte. 
1.3 Purpose 
Non-target analysis is a term commonly used in metabolomics and proteomics, where the 
identity of the analyte is a true unknown. Commonly, drug chemists analyze standards, or 
certified reference material, concurrently with case samples allowing for the manual comparison 
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of retention time and mass spectral features. Due to the never-ending cycle of new NPSs entering 
the illicit drug market, which results in standards not being available, non-target analyses are 
becoming increasingly common in forensic drug chemistry. Furthermore, drug chemists are now 
forced to determine whether the NPS is a new, uncharacterized analogue; a known, 
characterized, but unscheduled analogue; or a known, characterized, and scheduled analogue.  
Molecular structures fragment in predictable ways, namely, at the weakest bonds within a 
molecule. Mass spectrometry text books report that EI “mass spectra are excellently reproducible 
when measured under standard conditions… This is not only the case for repeated measurements 
on the same instrument, but also between different types and brands of mass spectrometers”19. 
Because the EI fragmentation patterns are shown to be reproducible and the %RAs are presumed 
to be, a common strategy for non-target identifications is using mass spectral library searches. In 
a library search, all m/z values and corresponding %RAs within an unknown spectrum are 
compared to known standard spectra within the library and a mathematical algorithm returns a 
match quality score. Different libraries may contain multiple search algorithms. For example, the 
National Institute for Science and technology (NIST) database contains two search algorithms, 
Identity Search and Similarity Search. The former algorithm searches for exact matches while 
the latter is designed to identify similar compounds; the optimization and testing of these 
mathematical algorithms is detailed by Stein et. al.28 Over the years, mass spectral libraries have 
been evaluated for quality of spectra29 and match correctness30, while inter-library comparisons 
have worked to identify potential errors in reference spectra31. The most recent search algorithm, 
termed the Hybrid Similarity Search, developed by NIST and for the NIST library allows for 
neutral-loss and fragment ion matching and is applicable to illicit compounds.32 This search can 
classify and identify compounds not already in the database by predicting shifts due to 
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substituent changes; however, successful prediction requires the molecular mass to be known.32 
It has been well documented that synthetic cannabinoids often do not produce molecular ion 
peaks.7 These advancements increase the potential that identifications, or suspected 
identifications, will result from non-targeted analyses, but without a known molecular mass is 
not universally applicable to NPSs. 
The variation, repeatability, and reproducibility of the GCMS data used for compound 
identification has not been extensively studied; relevant work is detailed below. It is also worth 
noting that although HDX has been shown to discriminate small glycan isomers with minute 
differences24, this technique has not, to date, been applied to NPSs. Historically, retention time 
and RI variation has been investigated intermittently. Temperature programmed RIs from 
pesticides and fatty acids were shown to be highly reproducible, even after the column length 
was changed for regular maintenance.33 More recent work by Davidson et. al34, assessed the 
uncertainty of retention times produced from various illicit drugs and compared the inter-
laboratory results to existing guidelines, like those set forth by the UNODC.34 It was shown that 
the measured uncertainty was smaller than the uncertainty criteria in the guidelines.34 However, 
retention times are not universally comparable, in that, they are dependent on instrument settings. 
This work also evaluated the inter-laboratory uncertainty of ion %RAs; the results indicated that 
the uncertainty was similar to the acceptance criteria, but that the %RAs are not independently 
variable within a spectrum, i.e. the uncertainty of ions is not independent of fragmentation 
pathways.34 Little work has evaluated inherent variation within GCMS instruments and across 
vendor platforms, which, anecdotally, is assumed to be negligible.  
With these studies in mind, this body of work had two specific aims focusing on the 
evaluation of non-target NPS analyses. 
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(1) investigate the inherent variation within GCMS instrumentation from different vendors 
(2) investigate if HDX-IMS-MS was capable of NPS isomer discrimination. 
Understanding the inherent variation in GCMS instrumentation and investigating strategies to 
limit the variation, provides information about how well drug chemists are identifying true 
unknown NPS analogues. Next, if isomer discrimination is possible with HDX-IMS-MS then the 
technique is capable of non-target analyses, albeit with limitations, as all other analytical 
techniques are subject to. 
This first aim was addressed in two studies. Initially, the ‘worst case scenario’ was 
evaluated by not conducting instrument tuning and vendor recommended maintenance over an 
extended time period. Next, the instrument intra- and inter-day variation was evaluated with 
regular tuning and maintenance. It was also determined if the instrument’s autotune passed 
tuning criteria set forth by the Environmental Protection Agency and investigated if passing this 
criterion reduced ion %RA variation. The second aim was addressed in a single study. Six NPSs 
were initially chosen to determine the propensity of deuterium exchange; next, HDX NPS isomer 
discrimination was evaluated using three disubstituted aromatic ring isomers (ortho-, meta-, and 
para-). 
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2.1 Introduction 
Novel psychoactive substances (NPSs) are a family of synthetic compounds designed to 
mimic the effects of other illicit drugs.1-2 The two largest categories of NPSs are synthetic 
cannabinoids and designer cathinones; other classes include piperazines, tryptamines, and opioid 
mimics. Although NPSs are currently regulated by various agencies worldwide, these regulations 
are largely limited by the compound structure.3-6 Small side chain substitutions and minor 
structural changes, which have varying effects on pharmacological activity, allow new analogs to 
temporarily evade these drug regulations.1-3 Amendments, like the Anti-Drug Abuse Act of 1986 
in the United States7, were created to extend legislation to analogues of specific classifications of 
controlled substances, so long as these analogues are sold for human consumption.7 To 
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circumvent amendments similar to this, two strategies have been used. Initially, NPSs were sold 
as ‘legal highs’, ‘research chemicals’, ‘plant food’, among other names, with various disclaimers 
such as “not for human consumption” and “for research purposes only”.1-2, 4, 8 Later, synthesis of 
substances with little structural analogy to controlled substances but similar pharmacological 
properties were pursued.5 This legislative limitation has created a revolving door of NPSs where 
a new analogue is readily available to act as a replacement once another has been scheduled.6, 9 
This cycle has created two problems for the forensic science community- non-availability of 
standards9 and numerous isobaric variants of similar core structures have been synthesized. 
While the lack of standards may preclude definitive identification for legal proceedings, the 
ability to identify NPSs is still critical for investigative and intelligence purposes. In the forensic 
laboratory setting, this implies reliance on comparison with spectra published in databases.  
Currently, gas chromatography-mass spectrometry (GCMS) is the most commonly 
employed instrument for the analysis of seized NPSs in a forensic setting. As such, retention 
time can be used as a part of the analytical identification scheme, particularly when comparing 
an unknown to a reference compound. However, with NPSs, standards often are not available 
and analysts must fall back on mass spectral interpretation and chromatographic behavior to 
postulate the identification of an unknown. In this context, retention time can be valuable as long 
as these values are comparable across instruments. A retention index (RI) method was proposed 
by Kovats more than 50 years ago as a means to do so in an era when MS was not widely 
available as a GC detector.10 The RI of an analyte is the expression of the retention time relative 
to the two n-alkanes that elute immediately before and after the target analyte. While this 
necessitates that an n-alkane solution, or “carbon ladder”, be analyzed contemporaneously, the 
advantage is that the RI value is more independent of experimental conditions than retention 
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time. Thus, while retention times can vary with column type, temperature program, etc., the RI 
remains constant within a range of variation. Furthermore, a RI value can be used in an analytical 
identification scheme by including or excluding potential NPSs. However, to integrate RI in this 
way, the uncertainty, or variability, of RI values must be established. This was one of the goals 
of this study. 
Several analytical challenges have arisen in the last decade that has revived interest in 
RIs. The term “non-target” analysis can refer to NPSs as is the case here, or to metabolomics or 
other “-omics” in which identification of a compound that cannot be confirmed by comparison to 
reference standards. Instead, identification relies on instrumental data such as mass spectra and 
retention time. There are two methods for calculating RI depending on the temperature settings 
of the gas chromatograph (isothermal vs. temperature programmed). Some mass spectral 
libraries contain RIs, either predicted by modeling or experimental, which can eliminate 
compounds during an identification search.10-14 One recent study investigated the reproducibility 
of program temperature RIs by varying the chromatographic experimental conditions.15 The 
authors did not report statistical values but indicate that RIs were nearly constant, even if the 
capillary column was shortened for maintenance, so long as there is constant carrier gas velocity. 
However, this study was conducted on a single instrument and column and lacked a quantitative 
metric to describe variability.15  
Although standards can be purchased and mass spectra can be manually compared, mass 
spectral fragmentation patterns can also be searched against comprehensive library databases, 
like SWGDRUG (for seized drugs and NPSs) and NIST (broadly).3, 6, 9, 16 However, the pace of 
standard availability and database updates inevitably lags behind the pace of the introduction of 
new NPSs.16 Even when trustworthy standard spectra are available through these entities, the 
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identification of a substance as being one in the database or as something not in the database 
relies on factors often taken for granted. This study explores two of these underlying and often 
unappreciated factors- the uncertainty (variability) of RIs across instruments and the variability 
of mass spectral patterns across instruments. Without knowing these uncertainties, any 
identification (or elimination) based on comparisons becomes problematic. Recent publications 
acknowledge the complications of NPS identification in this regard. For example, authors have 
noted problems distinguishing compounds with complex fragmentation patterns because the 
pattern loses specificity9; other authors have advocated for high resolution mass spectrometry for 
the identification of new synthetic cannabinoids.17 This would certainly be an improvement over 
typical electron impact MS systems, but high resolution MS does not solve the problem of 
isobaric compounds commonly seen in the world of NPSs. Thus, to assist investigators in 
accessing mass spectral comparison, a second goal of this study was to establish how much 
variation is expected to be observed in mass spectra (in terms of relative ion abundance) within 
and between instruments over time as a function of column, experimental conditions, and tuning 
criteria. 
Few studies of mass spectral variability were located in the context of non-target 
compound identification. Alternatives to database searching have been developed for 
metabolomics data processing. One such cloud based program is the XCMS Online.18 Although 
originally the platform was only capable of two group analysis, the platform continues to be 
updated and now allows for multiple group and meta-analysis and is capable of the 
deconvolution of metabolomics data from a number of instrumental designs.19 In 2017 Yu et al.20 
adapted the XCMS input functions to explore electron impact (EI) gas chromatography (GC) MS 
full-scan mass spectral profiles of trace environmental samples.20 Using a boundary regression 
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model the authors were able to decrease the analysis uncertainty by identifying and separating 
peaks likely contributable to noise.20 However, the authors used raw mass spectral peak 
intensities rather than percent relative abundances, which are used for database searching. Peak 
deconvolution, although shown to decrease analysis uncertainty for metabolomics, may not be 
easily applicable to forensic drug chemistry analyses. 
Initially, the project goals included developing models to generate quantitative estimates 
of uncertainty in RIs and mass spectral abundances. In this context, uncertainty is defined as the 
range of values which can reasonably be attributed to the measurand such as RI and percent 
relative abundance (%RA) of a given m/z ion.21 Several methods are used for estimating 
measurement uncertainty.21-23 Often, measurement uncertainty is closely linked to method 
validation and derivation of figures of merit.24-26 One of the challenges of estimating uncertainty 
in the context of GCMS and NPSs is how to capture and express variation across instruments and 
laboratories. For example, if one laboratory uses vendor A’s GCMS, vendor B’s column, and 
instrument tuning criteria “C”, while a laboratory in another jurisdiction uses completely 
different materials, estimation of uncertainty necessitates capturing the variation in RI values and 
mass spectral patterns associated with these different conditions. An uncertainty estimation 
process requires quantitative data regarding repeatability and reproducibility. Before such an 
estimate can be made, procedural steps to determine the amount of and minimize the existing 
variation must be performed. 
The goal of this study was to evaluate variation in RI and ion %RA among and between 
16 NPSs on GCMS instruments from three manufacturers using different instrumental settings, 
columns, tuning criteria, and usage patterns. The descriptive statistics of variables (RIs and mass 
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spectral %RAs) for each compound were collected and evaluated for significant differences at 
=0.05. 
2.2 Materials and Methods 
2.2.1 Chemical and Reagents 
LCMS grade purity methanol and hexane obtained from Fisher Chemical (Fair Lawn, NJ) 
was used for the NPS mixes and the carbon ladder solutions, respectively, as well as solvent 
blanks. The C7-C40 ladder standards were obtained from Supelco Analytical (Bellefonte, PA). 
NPS standards were obtained from Cerilliant (Round Rock, TX) and Cayman Chemical (Ann 
Arbor, MI). 
Three drug mixes containing ~15 ppm of each NPS, one 50 ppm carbon ladder solution, 
and two solvent blanks (methanol and hexane) were made for each instrument.  NPSs were 
separated into 3 solutions based on retention time- where a minimum of 0.4 minutes separated 
the compounds; the contents of the solutions are shown in Table 2.1. As this study was not 
quantitative, the actual concentration of each NPS was approximated and instead the NPS 
concentrations were adjusted (within 5 ppm) to ensure adequate GC signal intensity (30% 
normalized) for analysis. A low concentration of individual analytes was purposefully targeted, 
as this is where the most variation is anticipated to exist in mass spectral abundance patterns. 
 
 
 
 
 
26 
 
Table 2.1. NPSs contained in each of the three mixes. 
Mix Compounds 
Blue 
2,5-dimethoxy-4-iodoamphetamine 
25I-NBOMe 
Amphetamine 
Butylone 
JWH-018 
Red 
1-(3-chlorophenyl)piperazine 
4-fluoroamphetamine 
25C-NBOMe 
Benzyl piperazine 
UR-144 
Yellow 
5-MeO-AMT 
Dimethyltryptamine 
MDMA 
Mephedrone 
AH-7921 
2.2.2 GCMS Instruments 
Prior to analysis, each instrument underwent the regular maintenance of ionization source 
cleaning, column clipping, and changing the inlet liner. The Agilent (A) was tuned periodically 
up to 2 times per week while the Perkin Elmer (B) and Shimazdu (C) were tuned once for the 
duration of the experiment prior to first analysis. All instruments were tuned using the respective 
autotune feature and perfluorotributylamine (PFTBA) as a tuning compound. The instrument 
models and method settings for each instrument are shown in Table 2.2. Instruments A and B 
were used for two and one additional projects, respectively, resulting in an almost 24/7 analysis 
time for the duration of the study. Instrument C was used solely for this project resulting in less 
overall analysis time.  For this initial study, a variety of experimental conditions such as columns 
and settings were purposely selected to encompass the range of conditions typical across forensic 
laboratories.   
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Table 2.2. Model number and method settings for GCMS systems. 
 Setting A B C 
GC 
Model 7890B Clarus 680 GC-2010 
Column Type HP-5 ZB-5MS ZB-5MSi 
Column L X ID X df (m X mm X m) 30 X 0.25 X 0.25 20 X 0.18 X 0.18 30 X 0.25 X 0.25 
Injection Temperature (°C) 250 280 270 
Initial Column Temperature (°C) 100 100 100 
Final Column Temperature (°C) 320 320 305 
Ramp (°c/min) 15 15 10 
MS 
Model 5977AMSD Clarus SQ 8 S QP2010S 
MS Source Temperature (°C) 250 250 225 
EM Voltage (V) 1910 1792 1080 
MS Scan Range (m/z) 40-400 40-400 40-500 
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2.2.3 Experimental Design and Data Analysis 
A complete sample set, analysis order shown in Table 2.3, was then collected on each 
instrument periodically. A dataset was accepted for analysis if: there was no instrument error 
during the sample set, all solvent blanks were uncontaminated, and there was adequate GC signal 
intensity for peaks to be well defined, see Figure 2.1 for a flow chart. 
Table 2.3. Complete analysis in order which were performed. 
Position in Analysis Sample 
1 Hexane solvent blank 
2 C7-C40 ladder solution 
3 Hexane solvent blank 
4 Methanol solvent blank 
5 Red mix 
6 Methanol solvent blank 
7 Yellow mix 
8 Methanol solvent blank 
9 Blue mix 
10 Methanol solvent blank 
 
 
Figure 2.1. Flow chart of how a sample set was determined to be included or discarded. 
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For all datasets deemed acceptable, the retention times were recorded and RIs were 
calculated based on the temperature programming RI equation, Equation 2.1.10 
𝐼𝑥 = 100(𝑛 +
(𝑡𝑥−𝑡𝑛)
(𝑡𝑁−𝑡𝑛)
)          Eq. 2.1 
where Ix is the RI of the compound of interest, n is the number of carbon atoms in the alkane 
eluting just prior to the compound. tx is the retention time of the compound of interest, tn is the 
retention time of the alkane eluting just prior to the compound of interest, and tN is the retention 
time of the alkane eluting just after the compound of interest. 
To obtain the representative mass spectrum for each peak, the spectra across the middle 
of the peak (as estimated using full-width half-max) were averaged and the background from 
before and after the peak was subtracted. This procedure ensured that the mass spectrum 
subjected to further processing was not biased based on where it was observed across the elution 
profile. From this spectrum, the %RA and m/z value of the 20 most abundant mass spectra peaks 
were recorded. The datasets for each NPS and all instruments were then combined for data 
analysis by transcription into Excel data files. Data entry and transcription was independently 
checked for each batch of samples analyzed, extracted, and organized into spreadsheets. 
 Once all datasets were combined the average %RA for each of the most abundant mass 
spectra peaks was calculated. If the three-system %RA average was below 2% the peak was 
removed from the data set to prevent peaks associated with noise from being included in the 
statistical analysis. Descriptive statistics and one-way ANOVA analysis was conducted in 
OriginLab® (OriginLab Corporation, Northampton, MA). 
2.3 Results and Discussion 
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The number of acceptable datasets from each instrument was A (n=9), B (n=14), and, C 
(n=6) for a total sample set of n=29. The percentage of datasets deemed acceptable was 82%, 
74%, and 60% for instruments A, B, and C, respectively. The majority of the ‘unacceptable’ 
datasets were due to missed injections, where a single compound mix or the carbon ladder were 
missing, or due to an autosampler error and all three compound mixes were not collected. 
Instrument B operated for the longest time span of ~12 weeks, whereas instrument A and C 
operated for ~8 weeks and 4 weeks, respectively. 
2.3.1 Retention Indices 
The RIs for 4-fluoroamphetamine and amphetamine on instrument C could not be 
calculated because on the columns used, the corresponding n-alkane co-eluted with the solvent. 
The descriptive statistics, shown in Table A1, details the variation and repeatability of RIs for 
each instrument. The RSD across all systems and compounds was 0.35%, as expected, which 
emphasizes the potential value of incorporating RI in any cross-identification scheme. 
Interestingly, a means comparison of the RIs (Figure 2.2) showed significant differences 
between the three systems despite the small overall %RSD. As seen in Figure 2.2, statistically 
significant differences, shown in red, were identified in 39 of the 44 comparisons. One 
possibility is that differences in the column aging and degradation generated variation between 
instruments. A second possibility is that the variation resulted from differences in temperature 
programming and column type. Despite the statistical differences and regardless of the cause, the 
largest difference in RI between any two instruments for a single compound was 37.0 RI units. 
This reiterates the utility of incorporating RIs in non-targeted analysis. For example, if a mass 
spectral library search returns 50 potential matches, a comparison of RIs would be able to 
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eliminate potential matches because the RIs are outside of a determined uncertainty range. 
Identification of this range will require further studies. 
 
Figure 2.2. Means comparison of RIs for all NPSs. 
2.3.2 Mass Spectra 
2.3.2a Mean Relative Abundance Comparisons 
The number of specific m/z ions included in the statistical analysis for each NPSs ranged 
from 10 to 17 depending upon the “richness” (number of fragment peaks above 2% RA three 
system average) of the spectrum. An example of a feature-poor and feature-rich mass spectra are 
shown in Figures 2.3a and 2.3b, respectively. Ions of 100% RA (base peak) were included only 
if the selected peak was not consistently the most abundant; i.e. 100% in one instance and 95% 
in another. Alternating base peaks occurred with three NPSs: JWH-018, 5-MeO-AMT and UR-
144. As will be discussed later, this type of variation can create a cascading effect across all 
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associated %RAs. If a given m/z is always 100%, the variation is zero; when the base peak 
changes, variation increases across all peaks because the basis (m/z identity) of the %RA 
changes. 
  
Figure 2.3a. Example of feature-poor spectra (amphetamine). 
 
 
  
Figure 2.3b. Example of feature-rich spectra (JWH-018). 
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Prior to data collection, two hypotheses were developed regarding variation, as measured 
by %RSD, in mass spectral %RAs. The first was that the variation would increase for ions on the 
extremes of the instrument’s scanning range capability. If this were the case, a plot of %RA as a 
function of m/z value would be a parabolic shape; this pattern was not observed. The second 
hypothesis was that the %RSD would increase as the %RA decreased; i.e., the variation in an m/z 
peak of 2% RA would be expected to be greater than that of an m/z peak with a RA of 60%. This 
would result in a pattern similar to an exponential decay function with a large decay constant. 
When the experimental data was plotted (Figure A1a), this generalized pattern plot was 
observed, but was not sufficiently consistent to fit. Differences between the data from the three 
systems was evident- instrument C did not fit the exponential decay pattern as consistently as 
instrument A and B (Figure A1b).  
A three-dimensional plot of m/z, %RA, and %RSD and a projection plot for data from all 
three instruments are shown in Figures A2 and A3, respectively. Apparent outliers were seen in 
Figure A2 (boxed region). These points represent m/z values present at RAs >>%2 in two 
instruments but at a much lower and inconsistent %RA in the third instrument. Because the 
three-system average %RA of these m/z values exceeded 2% RA, the values met the criteria 
discussed above and were not removed from the dataset in the initial screening.  This produced 
the high %RSDs observed. In addition, instruments A and C had more data points with >100% 
%RSD than instrument B. These instruments had fewer datasets, which may have attributed to 
the increased frequency of data points with high variation. To determine if averaging the %RA of 
ions over the course of the study was obscuring predictor trends, the %RA of ions from feature-
poor and feature-rich compounds were plotted as a function of time. No recognizable pattern was 
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elucidated from the data. Descriptive statistics for the top five ions of select NPSs are detailed in 
Table A2 and were considered representative of the complete dataset. 
An exhaustive means comparison analysis was performed for all NPSs, all m/z values 
retained based on the criteria described earlier, and as obtained on all three instruments. The 
results are summarized in Figure 2.4. Instruments A and B most frequently had no significant 
difference in means (shown in green), but beyond that, little can be said with confidence other 
than the means differences between instruments are common with no discernable pattern. 
 
Figure 2.4. Means comparison of %RA of five most abundant ions for all NPSs. 
Ions are in decreasing order of abundance. Base peak only included if it alternated  between two 
or more ion values during the study. 
 
Select mass spectra from various NPS classes with means comparison box charts for the 
top three most abundant ions are shown in Figures 2.5, 2.6, and A4-A8. The range, as illustrated 
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in the box plots, indicated that instrument A showed the least within instrument variation, which 
is postulated to be due to the increased tuning frequency compared to the other two. The range 
for instrument C, on the other hand, consistently showed the largest within instrument variation. 
It is possible that this large variation may be caused, in part, by the small number of datasets 
from this instrument included in the statistical analysis. For feature-poor spectra the amount of 
within instrument variation for instrument B was between A and C, shown in Figures 2.5a-c. 
However, for feature-rich spectra (Figures 2.6a-c) the range is inconsistent, i.e. occasionally 
smaller than instrument A or larger than instrument C. This was due to an irreproducible base 
peak, discussed in detail below. 
 
 
Figure 2.5a. Amphetamine box means comparison chart for m/z 91. 
Most abundant ion. Note the y-axis scale change. 
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Figure 2.5b. Amphetamine box means comparison chart for m/z 65. 
Second most abundant ion. Note the y-axis scale change. 
 
 
  
Figure 2.5c. Amphetamine box means comparison chart for m/z 42. 
Third most abundant ion. Note the y-axis scale change. 
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Figure 2.6a. JWH-018 box means comparison chart for m/z 341. 
Most abundant ion. Note the y-axis scale change. 
 
 
 
Figure 2.6b. JWH-018 box means comparison chart for m/z 284. 
Second most abundant ion. Note the y-axis scale change. 
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c)  
Figure 2.6c. JWH-018 box means comparison chart for m/z 214. 
Third most abundant ion. Note the y-axis scale change. 
2.3.2b Irreproducible Base Peaks 
Three instances of irreproducible base peaks are discussed in detail. The first situation 
occurred on a single instrument, where the base peak alternated between multiple ions on a 
single instrument. Alternating base peaks on a single instrument are particularly troublesome in 
that a ripple effect impacts all related %RA values. When the base peak is stable, the 
denominator of the %RA calculation is a constant; when the base peak changes, the denominator 
is also a variable. This essentially changes the identity of the %RA calculations, which causes an 
increase in the variability of all other %RAs. The second instances of irreproducible base peak 
changes are considered anomalies and are discussed below. The final instance of an 
irreproducible base peak occurred with 5-MeO-AMT. This base peak was inconsistent between 
instruments, where each instrument produced a single base peak but the base peaks were not 
necessarily the same. The “ripple” effect was not present in this case because the identity of the 
%RA calculations did not change for any one instrument. Each situation is important to discuss 
in detail as either scenario could hinder proper identification of the NPS. 
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The first instance of an alternating base peak occurred with JWH-018, where the base 
peak altered between m/z values of 341, 214, 127, and 43. The peak at m/z 341 was most 
frequently the base peak across the three instruments and was the only base peak in the spectra 
obtained on instrument A. Instrument B’s base peak alternated between m/z 341, m/z 214, and 
m/z 127. These ions were present at a RA of 70-100% in all datasets associated with instrument 
B. These four ions were present in instruments A and C at RAs of 40-60%. This observation is 
significant given that instrument B was tuned once but produced the most variable base peak, 
while instrument A produced a single base peak but was tuned most frequently. Clearly, tuning 
frequency is a critical factor in variability of m/z %RA values.  
The next instances of alternating base peaks occurred on instrument C for both JWH-018 
and UR-144. Instrument C was the only instrument to produce m/z 43 as a base peak for JWH-
018. This ion was not present in the 20 most abundant ions on instrument A but was present in 
data associated with systems B and C. The RA ranged from 20-40% on instruments B and C with 
the exception of the final two C datasets where the RA was recorded at 78% and 100%. 
Instrument C was the only instrument to produce m/z 43 as a base peak and it only occurred 
once. A similar situation occurred with a base peak change for the compound UR-144; the mass 
spectra with box charts is shown in Figure A7. m/z 214 was the base peak for all datasets except 
the final C dataset where m/z 41 was. This ion had a RA of 5-20% on instruments A, B, and C 
with the exception of the final two C datasets where the RA was recorded at 92% and 100%. It is 
unclear what caused the base peak change for the JWH-018 and UR-144 instrument C datasets. 
These base peak changes are considered anomalies. 
The final instance of an irreproducible base peak occurred with 5-MeO-AMT, but in this 
case, the ripple effect was not observed (Figure A8). The base peak of 5-MeO-AMT for 
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instruments A and B was m/z 161; however, the RA of m/z 161 on instrument C ranged from 20-
60%. The base peak for all datasets associated with instrument C was m/z 44. The RA of this ion 
was approximately 50% for instrument A, but ranged from 50-90% for instrument B. The high 
%RA observed on instrument B indicates that it may have been possible for the base peak to 
alternate between from m/z 161 to m/z 44 on this instrument. Had this alternation occurred, the 
identity of the %RA calculations would have changed and the “ripple” effects that were seen 
with JWH-018 would have been present. This issue clearly shows where the use of RI would be 
of value for identification purposes. Irreproducible base peaks, either between instruments or on 
a single instrument, may hinder identification of NPSs by preventing mass spectral 
fragmentation patterns to be effectively compared. RIs were shown to be reproducible and 
repeatable and provide an additional means of data comparison for compound identification. 
2.4 Conclusion and Next Steps 
The variation, repeatability, and reproducibility of RIs and %RAs of mass spectra 
fragmentation peaks were investigated across three instrument systems. There were statistically 
significant differences in the means of RIs between instruments. However, the overall RSD was 
<0.35% and the largest difference in means was shown to be 37.0 RI units. This demonstrates 
that the RI is sufficiently reproducible to be used as part of compound identification or, more 
likely, to eliminate potential identifications during non-targeted analysis. This ability could be 
useful in the context of isobaric compounds in which the spectral patterns are indistinguishable. 
Based on the data here, the difference between an experimentally obtained RI should fall within 
± approximately 37 RI units of the known or reference value.  
The %RAs of mass spectra showed variation ranging from <1.0% to ~250% RSD on 
individual instruments. The differences in variation on instrument systems is postulated to be 
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linked to tuning criteria and frequency. The most frequently tuned instrument, instrument A, was 
shown to consistently have the smallest %RA variation of the three instruments. Instrument B, 
which was tuned once prior to first analysis, had the most irreproducible base peak for JWH-018. 
Although the cause of the alternating base peak is currently unclear, it is possible that increased 
tuning frequency would reduce the number of alternations and improve the variation of ion %RA 
on this system. 
The findings of this study clearly show that mass spectral patterns vary significantly 
between instruments and that a primary factor is detector tuning. Thus, when comparing spectral 
patterns of non-target compounds (no reference standards), this variability can be critical. 
Variation was also shown to be linked to the value of the %RA; lower abundance ions, 
commonly produced in feature-poor spectra like amphetamine, provide a wide range of variation 
from 2-25% RSD. On the other hand, ions with >20% RA typically never exceed 20% RSD. 
Intra-system variation was shown to be dependent on reproducibility of the base peak ion, which 
was problematic for feature-rich spectra, like the spectrum produced by JWH-018. RIs can be 
used as filtering information but will require that such data be generated. This is not current 
practice in most forensic laboratories.  
Two avenues are being explored based on the findings of this work- tuning frequency and 
tuning check compounds. Tuning check compounds are introduced into a tuned instrument and 
checked against stringent m/z abundance criteria. If not met, the tune is adjusted until a pass is 
obtained. This is not a new concept and was first widely applied starting in the 1980s associated 
with analytical methods promulgated by the Environmental Protection Agency. The use of 
tuning check compounds coupled to frequent tuning (daily or before every batch) is currently 
being evaluated as a method to reduce spectral variation. The check mix being studied also 
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includes a RI check which is being evaluated as a method to adjust for the small changes in RI 
that were identified in this work. It is the hope that a reasonable and easily adopted protocol for 
using the methodology can be developed for use in NPSs analyses in the forensic setting. 
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3.1 Introduction 
Electron impact gas chromatography mass spectrometry (GCMS) is the key instrument 
for the analysis of seized drugs in a forensic setting.1 This technique utilizes retention times and 
mass spectral fragmentation patterns, typically compared against a reference standard, to confirm 
the structural identity of compounds. Developing new reference standards is a complex, time-
consuming process, described in detail elsewhere2; this process can only be started once a 
compound has been fully characterized. The rapid introduction of new novel psychoactive 
substances (NPSs) means there is initially no reference standard available to compare against 
case sample data. This lack of standards creates a unique issue because many isobars and 
isomeric derivatives have been identified and can produce nearly identical mass spectra. Without 
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reference standards for manual comparison, forensic laboratories rely on non-targeted library 
searches of mass spectral databases to postulate a tentative identification.3 In a library search, the 
percent relative abundance (%RA) of all m/z values in the mass spectra of an unknown analyte 
are compared to those of known mass spectra within a library. This yields a list of potential 
matches along with a score that characterizes the match quality. Verified identification of the 
new analog and a certified reference standard are required for the updating library databases with 
new compounds; the forensic community relies heavily on two databases: Scientific Working 
Group for the Analysis of Seized Drugs (SWGDRUG) for illicit compounds and National 
Institute of Standards and Technology (NIST) for broad searches.1, 3-5 Another useful library in 
seized drug analysis, particularly for NPSs, is the Wiley Mass Spectra of Designer Drugs 
(Scientific Instrument Services, Ringoes NJ), which contains more than 20,000 compounds 
related to NPSs. 
A critical and often unappreciated consideration is the inherent uncertainty in the %RA of 
the m/z values upon which identifications are proposed. Anecdotally, it appears as if intrinsic 
variability is assumed to be minimal on modern instruments utilizing vendor standardized 
parameter tuning (i.e., autotuning). However, a recent publication by our group demonstrated 
that this variation can be significant, up to 250% RSD, and as such must be taken into 
consideration when deciding tentative identifications. The previous study examined variation of 
%RAs for 16 NPSs analyzed on three instruments from different vendors. Time between tuning 
was one of several variables in this study. The results suggested that tuning frequency, as an 
experimental variable, was the most important factor relating to %RA variation.6  
The GCMS instruments used in process analytical chemistry, including seized drug 
analysis, utilize a tuning operation, referred to as autotune or tuning, in which PFTBA 
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(perfluorotributylamine) is bled into the mass spectrometer source. Specific fragment ions are 
used to calibrate multiple component settings of the detector. Typically, voltages applied to 
lenses are adjusted to optimize the abundance and ion ratio of the different fragment ions 
reaching the electron multiplier. Quadrupole gain and offset are adjusted to set the proper peak 
width and mass axis for assigning masses. Finally, the electron multiplier voltage is set to 
compensate for the gain adjustment allowing the latter to remain at a consistent value. What is 
deemed a ‘pass’ versus ‘fail’ if defined at all, is not standardized. As such the process of tuning 
alone does not necessarily guarantee minimal variation across vendor platforms. The tuning 
dilemma is arguably exacerbated in a forensic setting because individual laboratories define 
standards of practice, including tuning frequency and instrument maintenance guidelines, and 
validate instruments under different operational settings. 
The concern regarding comparability of mass spectra across vendor platforms is neither 
new nor unique to forensic applications. Decades ago, the Environmental Protection Agency 
(EPA) adopted the use of tune check compounds in order to address and reduce systematic 
variance within mass spectra; decafluorotriphenylphosphine (DFTPP) and bromofluorobenzene 
(BFB) were employed for semi-volatile and volatile analytes, respectively. In this approach, the 
instrument is tuned using the internal protocol and then a proscribed amount of a tune check 
compound is injected. The resulting spectrum, also generated by a proscribed processing 
procedure, is evaluated for specific m/z values. Table 3.1 shows the most recent criteria 
published by the EPA for DFTPP.7 In this protocol, all DFTPP criteria must be met before case 
samples are analyzed.  
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Table 3.1. EPA DFTPP Tuning Criteria. 
m/z Value Ion Abundance Criteria 
68 <2% of 69 
69 Present 
70 <2% of 69 
127 40-60% of 198 
197 <2% of 198 
198 Base peak or Present 
199 5-9% of 198 
365 >1% of 198 
441 Present, but <150% of 443 
442 Base Peak or Present 
443 15-24% of 442 
 
Over the years, instrument vendors have added algorithms that adjust the tune of PFTBA 
to meet DFTPP criteria and processing algorithms that can check injected DFTPP for acceptance. 
It is important to note that the DFTPP criteria addresses the ability to detect isotopic peaks as 
well as abundance issues across a m/z range that correlates well with most drugs of forensic 
interest. Accordingly, a study was designed to determine if this approach could be applied to 
seized drug analyses as a tool to minimize the variance of ion %RAs across instrument 
platforms. Specifically, the hypothesis set forth was that when detector parameters from an 
autotune produced a DFTPP spectrum are deemed a pass, the variability of the spectrum 
obtained contemporaneously with this tune will vary less than those obtained following a tune 
that resulted in a DFTPP fail.  
Somewhat surprisingly, the results showed that the DFTPP pass/fail outcome had no 
significant effect on the variability of %RAs, with the exception of cathinones. However, the 
differences were minimal and not substantial enough to recommend its use in a forensic setting. 
The results did demonstrate that tuning frequency, rather than tuning to specific criteria, is the 
key factor influencing variation within and between autotunes. Specifically, in this study a tune-
50 
 
then-run scheme was performed, and the results showed that the %RSD of %RAs decreased five-
fold compared to the previous study. Thus, it is recommended that forensic laboratories measure 
performance criteria, either from the autotune report or via a performance check that indicates 
unacceptable performance and to develop a schedule dictating when maintenance, ranging from 
column clipping to source cleaning, must be performed. Within these performance brackets, the 
autotuning process should be conducted immediately before each case sample batch to minimize 
variation in %RA values across vendor platforms.  
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents 
LC-MS grade methanol was purchased from Fischer Scientific (Fair Lane, NJ). The 
DFTPP standard was obtained from Supelco Analytical (Bellefonte, PA) and all NPS standards 
were obtained from Cayman Chemical (Ann Arbor, MI). For each instrument, a total of three 
solutions were prepared: the check solution and two drug solutions each containing three NPSs, 
one cathinone and two cannabinoids. The NPSs were selected to include a range of molecular 
weights and spectral features; Table 3.2 summarizes the mixtures and compounds utilized and 
the designated compound feature class, defined in section 3.2.3.  
Table 3.2. Composition of Check Mix and NPS drug mixes. 
Solutions Compounds 
Concentration 
(ppm) 
Feature 
Class 
Molecular Weight 
(g/mol) 
Check Solution DFTPP 100 -- 442 
NPS Solution 1 
NEB*a 150 Poor 191 
JWH-116 200 Rich 369 
JWH-200 250 Poor 384 
NPS Solution 2 
MeMABP*b 150 Poor 191 
JWH-149 200 Rich 369 
BB-22 300 Poor 384 
*Cathinone, aN-Ethylbuphedrone, b4-Methybuphedrone. IUPAC naming for all six compounds 
are shown in the abbreviations. 
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3.2.2 GCMS Instrumentation 
Prior to the start of the project, routine maintenance including source cleaning, replacing 
the injection syringe, column clipping, changing inlet liner, and changing the injection port 
septum was performed on both instruments, an Agilent (A) and a Perkin Elmer (B). The routine 
maintenance was performed as needed, i.e. manufacturer recommendations and/or instrumental 
indicators, throughout the duration of the study. The additional maintenance of sanding and 
cleaning the capillary inlet gold seal was performed on instrument B between days 6 and 7. This 
maintenance was performed due to a low inlet pressure warning along with significant changes 
in the retention time of DFTPP. These instrumental indicators are typically associated with the 
inlet liner and septum needing to be changed, however, this did not remedy the reduced pressure 
warning. Upon investigation, the gold seal was noticeably worn where contact occurs between 
the injector nut and capillary injector fitting. Resurfacing and cleaning resulted in the GC inlet 
properly maintaining pressure. 
The software used for both instruments include multiple autotune options including a 
‘basic’ autotune and an autotune which attempts to adjust tune settings so that a subsequent 
analysis of DFTPP would meet EPA criteria. Instrument A provides three separate autotune 
options (‘basic’, DFTPP, and BFB), the ‘basic’ autotune function was used. Instrument B 
provides two tuning options one labeled as “Custom (Autotune)” and one labeled as “Standard 
(DFTPP/BFB)” the latter was the tune method used for this study. Because instrument B does 
not have separate BFB and DFTPP options, it was assumed that the algorithm adjusts settings to 
meet both criteria. Instrument details and method settings are shown in Table 3.3. 
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Table 3.3. GC-MS systems details, method/instrument settings, and instrument/analysis software.  
 Setting A B 
GC 
Model 7890B Clarus 680 
Column Type HP-5 ZB-5MS 
Column L X ID X df (m X mm X μm) 30 X 0.25 X 0.25 20 X 0.18 X 0.18 
Injection Split Ratio 20:1 10:1 
Injection Temperature (°C) 250 250 
Initial Column Temperature (°C) 100 100 
Final Column Temperature (°C) 320 315 
Ramp 20 20 
MS 
Model 5977AMSD Clarus SQ 8 5 
Source Temperature (°C) 250 250 
EM Voltage 2504-2864 1685-1874 
Scan Range 
DFTPP Method: 40-500 
40-500* 
NPS Method: 40-400 
Software 
Instrument Control MassHunter GC/MS Acquisition Turbo Mass 
Version B.07.00 SP1.1549 6. 1. 0. 1983 
Data Analysis 
Version 
Qualitative Analysis 
B.06.00 
Turbo Mass 
6. 1. 0. 1983 
*The day 1 scanning range was 40-400. 
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3.2.3 Data Acquisition and Processing 
The process used to collect, screen, combine, and collate mass spectra data is summarized 
in Figure 3.1. Each instrument was tuned immediately prior to starting the day’s ‘analytical 
batches’. An analytical batch consisted of blanks, the check solution, and each NPS solution. A 
data set was defined as a single repetition of the check solution and ten (10) repetitions of each 
NPS solution (and all necessary blanks) within a single day. DFTPP tuning criteria was not 
checked at the time of analysis since it was not used as a criterion for deciding if analysis should 
continue. Analytical batches were repeated using this same process over 2 and 1.5 weeks for 
instruments A and B, respectively. Ten data sets for each instrument were collected over this 
time yielding a total of 100 mass spectra or analytical batches from each instrument for each 
NPS. 
 
Figure 3.1. Collection and collation of data procedure. 
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The mass spectra were obtained from the average across the chromatographic peak at the 
estimated FWHM followed by subtraction of the averaged background obtained prior to and 
after elution. The %RA of DFTPP criteria ions were calculated and were compared against the 
EPA criteria (Table 3.1) to determine whether the tune passed or failed. If all criteria ion RAs 
were within the established range, the tune was deemed a pass, oppositely, a tune was deemed a 
fail if a single ion %RA was outside of the criterion range. For each NPS, the %RA of the 20 
most abundant m/z values were recorded. The choice of 20 ions was selected based on prior work 
in our laboratory.6 Data was verified two additional times by at least two individuals after initial 
entry, once during data processing and again prior to statistical analysis. Spectra were 
categorized as feature-rich and feature-poor, a subjective description term defined during 
previous work.6 An example illustrating the difference is presented in Figure 3.2. Feature-poor 
compounds produce mass spectra with a limited number of fragment ions often in low 
abundance, while feature-rich compounds fragment extensively and ions have varying 
abundances.  
Once data collection was complete and collated for each compound, an initial data 
elimination was performed. Data was not eliminated based on an arbitrary %RA value or 
estimated S/N considerations, rather, a m/z value for a given compound was required to be 
present in more than 2.5% of the data sets to be included for further consideration. In other 
words, if a given ion from a compound was present in less than 5 spectra of the 200 collected, 
that m/z value was eliminated. Data analysis was then conducted using OriginLab® (OriginLab 
Corporation, Northampton, MA).  
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Figure 3.2. Comparison of spectra classified as feature-rich and feature-poor. 
 The x-axis is %RA and y-axis is m/z value. Both spectra originated from instrument A, day 4, 
analytical batch 2. Maximum signal intensity is shown to demonstrate spectra are not result of 
weak detector signal. 
3.3 Results and Discussion 
The data was evaluated to address three questions: 
1. Does the use of DFTPP as a tuning check reduce variation of %RA values? 
2. How does tuning frequency impact this variation? 
3. Does the complexity of a spectrum (expressed as feature-rich/feature-poor) influence the 
variation of %RA under these conditions?  
3.3.1 Tuning to DFTPP Criteria 
3.3.1a Frequency of Pass/Fail 
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Instrument A passed 100% of the DFTPP tune checks while instrument B passed only 
20% (Day 4 and 10). The most frequently failed ion was m/z 68 followed by m/z 127; m/z 199 
failed to meet criterion on a single day. No ions above m/z 200 failed to meet EPA criteria. m/z 
199 was the only ion to fail to meet the criterion due to being under %RA threshold, this was by 
~0.5% RA. All other ions failed criteria due to being above the %RA criterion threshold. The 
largest and smallest fail was 3.1% and <0.1% above the %RA threshold, respectively. As 
previously mentioned the “Standard (DFTPP/BFB)” tuning option was used for instrument B. 
BFB is the lower molecular weight tune check compound utilized in EPA purge-and-trap 
methods for volatile organics and all criteria ions for this compound are less than m/z 200. Thus, 
the tuning algorithm may emphasize low mass ions which would explain the DFTPP ions failing 
criteria due to low mass ion %RAs being over the threshold. This supports the assumption that 
the tuning algorithm adjusts settings to attempt to meet both DFTPP and BFB criteria. 
3.3.1b Effect of Pass/Fail on Variability 
If passing the DFTPP criteria reduced ion %RA variation, then data associated with 
passing tunes should demonstrate less variability than data collected on days when the tune 
criteria was not satisfied. Since failing tunes were only noted with Instrument B this was the only 
data considered. Results are summarized in Figures 3.3a-c.  
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Figure 3.3a. Mean % relative abundance per day for select ions from NEB separated by DFTPP 
tune pass and fail days. 
Only instrument B was considered (n=10). Note the y-axis scale change. Error bars indicate one 
standard deviation. 
 
 
Figure 3.3b. Mean % relative abundance per day for select ions from JWH-200 separated by 
DFTPP tune pass and fail days. 
Only instrument B was considered (n=10). Note the y-axis scale change. Error bars indicate one 
standard deviation. 
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Figure 3.3c. Mean % relative abundance per day for select ions from JWH-149 separated by 
DFTPP tune pass and fail days. 
Only instrument B was considered (n=10). Note the y-axis scale change. Error bars indicate one 
standard deviation. 
 
Some ions show a significant between-day variability such as NEB m/z 41, 58, and 87; 
JWH-200 m/z 127; and JWH-149 m/z 115; these ions also had increased within-day standard 
deviations relative to the ions showing consistent between-day mean %RAs. Both patterns held 
regardless of DFTPP pass/fail criteria. This suggests that patterns of within-day variation follow 
patterns of between-day variation and that the DFTPP pass/fail criteria is not significant 
contributing factor. A second, but similar, observation derived from Figure 3.3 is that there are 
several m/z values that show little inter- and intra-day variability such as m/z 91 and 162 from 
NEB; m/z 98, 254, and 284 from JWH-200; and m/z 254, 313, and 352 from JWH-149. These 
patterns were also consistent regardless of DFTPP performance which further suggests DFTPP 
criteria outcome is not a significant factor in variation reduction. This also suggests that other 
underlying factors contribute to the degree of variability observed. 
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A t-test of means and a f-test of variance was performed comparing the pass/fail 
groupings (α=0.05). The results are summarized in Figure 3.4. Two feature-poor spectra (NEB 
and MeMABP) had the most statistically significant differences between mean relative 
abundances for passing versus failing the DFTPP tuning criteria. However, this pattern does not 
hold for the cannabinoids. The results for both feature-poor and -rich cannabinoids is split, where 
one compound consistently shows statistically significant differences in mean and variance, but 
the other compound from the same feature class does not. This is further evidence that the 
pass/fail criteria is not a significant factor in %RA variability and the implementation of DFTPP 
tune checks within a forensic setting would be of little value.  
 
 
 
Figure 3.4. Comparison of performance as a function of tune pass/fail. 
*: Cathinone. BB-22 and JWH-200 are feature-poor cannabinoids, JWH-116 and JWH-149 are 
feature-rich cannabinoids. Ions shown are five most abundant ions in decreasing order from 
instrument B. For the f-test the null hypothesis was considered to be that the variances from the 
two groups were equal. 
3.3.2 Relative Abundance 
3.3.2a Within-Day Variation 
Previous work in our lab showed that %RSD tends to increase exponentially as mean 
%RA decreases.6 A similar pattern was observed in this study (Figure B1). The highest recorded 
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%RSD in the present study was ~49%, a 5-fold reduction compared to the initial study.6 Given 
that the DFTPP pass/fail criteria did not have a significant impact on variability, the remaining 
factor is tune frequency. Thus, assuming a detector is operating within a defined range of 
acceptable performance, tuning as close to analysis time as possible is the key factor in 
minimizing variance in %RA.  
To determine if one compound classification produces more variation than another, the 
plot described above was separated by the feature class designations (Figure 3.5). Feature-poor 
cannabinoids produced the most data points with ≥15% RSD, 23 ions, followed by feature-rich 
cannabinoids, 6 ions, cathinones produced the least with only 4 ions. Regardless of mass spectral 
richness, synthetic cannabinoids have comparatively more complex structures than cathinones, 
which suggests that structural complexity may contribute to %RA variation. However, the 
current data does not provide the information necessary to determine the exact source(s) of the 
observed differences.  
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Figure 3.5. Relative standard deviation plotted as a function of the mean relative abundance 
from single day analysis sets (n=10) from all NPSs and separated by NPS category and sub-
class. 
 
The current data indicates that consistent tuning, within-day variation generally lies 
≤15% RSD but, is reliably within 50% RSD. This poses unique challenges for NPS 
identification, particularly in a forensic setting, as isomeric structures can produce near identical 
spectra. In a scenario where a non-targeted analyte identification is dependent on the %RA of a 
handful of ions, accounting for a 50% RSD within each individual %RA poses a challenge. In a 
more complex scenario, two structural isomers may have different scheduling classifications but 
nearly identical spectra. Identification of the specific structural isomer determines whether a 
suspect is in possession of an illegal substance or an unregulated, legal substance; here, 
accounting for the mass spectral variation is even more crucial. In either scenario, other 
information is relied upon or additional analyses are performed to make identifications, for 
instance GC retention times/indices and DART-TOF, respectively. However, the large %RSD 
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reported here highlights the importance of utilizing all information or performing multiple 
analyses in complex, non-targeted isomer identifications. 
3.3.2b Between-Day Variation 
An important goal of this study was to investigate data trends and variation from both 
within a single autotune as well as between different autotunes. Initial examination of the latter 
was performed by creating group plots of all recorded %RAs for individual ions (Figures B2a-
c). The same trend described in section 3.3.1b is seen, where some ions show consistent %RAs 
over the course of the study while others vary drastically. In theory, a single autotune should 
produce nearly identical mass spectra for a single compound. Under this premise, the %RA 
means from individual days were calculated for ions and formatted into similar group plots 
(Figures 3.6a-c). 
Although the same trend continues, where some ions have comparably more consistent 
%RAs than other ions, instrument A produces less between-day, and therefore between tune, 
variation than instrument B. As described above, instrument B tune checks failed mainly due to 
criteria ions below m/z 200 having %RAs over the threshold. Synthetic cathinones in this study 
only produced ions below m/z 200 (Figures 3.6a and B3a) whereas synthetic cannabinoids 
(Figures 3.6b, 3.6c, B3b, and B3c) produced ions above and below m/z 200. Specifically 
looking at instrument B, ions above m/z 200 show more between-day %RA consistency than ions 
below the threshold. Because the m/z threshold value is identical for both tune check fails and 
between-day consistency differences, it is hypothesized that the between-day inconsistency of 
low mass ions is largely due to tune biasing. Here, ions below the m/z 200 threshold have an 
innate tuning bias to meet the EPA criteria for BFB as a tune check compound. Because the 
autotune parameters are more variable below this threshold, due to the tuning algorithm 
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attempting to meet both DFTPP and BFB criteria, the low mass mean %RAs have a higher 
variability between days. 
It could be argued that this trend is observed on instrument A for JWH-149 (Figure 3.6c) 
because of the variability differences above and below m/z 200, for example comparing m/z 115 
and m/z 352. However, the ion %RAs of NEB and JWH-200 are more consistent between days 
(Figures 3.6a and 3.6b) suggesting that this is not the case. In other words, these ions show 
consistent between-day means regardless of the m/z value and therefore the variability trend 
describe for instrument B is not present on instrument A. It is believed this trend is specific to 
instrument B and a result of the tuning bias toward lower masses. 
 
Figure 3.6a. Mean RA per day for select ions from NEB. 
n=3 to 10 depending how many times the ion was recorded each day. Note y-axis scale change. 
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Figure 3.6b. Mean RA per day for select ions from JWH-200. 
n=3 to 10 depending how many times the ion was recorded each day. Red lines indicate 
threshold of m/z 200 where ion variation from instrument B comparatively decreases. Note y-
axis scale change. 
 
  
Figure 3.6c. Mean RA per day for select ions from JWH-149. 
n=3 to 10 depending how many times the ion was recorded each day. Red lines indicate 
threshold of m/z 200 where ion variation from instrument B comparatively decreases. Note y-
axis scale change. 
 
3.3.2c Ion Variation and Fragmentation Correlation 
As a final note, an underlying trend was consistently present within the data. Some ions 
showed consistent within- and between-day %RAs as measured by single day standard 
deviations and consistency of mean %RAs, respectively. Other ions showed variable within- and 
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between-day %RAs. This was initially postulated to be the result of differences in fragmentation 
patterns and/or the ability to fragment via multiple pathways. Two scenarios were hypothesized 
to contribute to the variation differences. Firstly, if an ion was formed through multiple 
fragmentation pathways then the variation would be higher and conversely if an ion could only 
be formed by a single pathway then the variation would be smaller. Secondly, if an ion was 
unlikely to be formed during a fragmentation event then the variation would be larger; for 
example, in a fragmentation event where one ion is statistically more likely to carry the charge, 
then the other ion fragment would be formed inconsistently and therefore have a higher 
variation. These hypotheses would also address the observation that the same m/z values from 
different compounds produced different amounts of variation. Both observations, which link 
fragmentation patterns/ability and variation differences, are similar to data reported by Jackson 
et. al.8  The authors reported that the uncertainty of fragment ions pairs were correlated, in other 
words, %RA uncertainty is not independent of fragmentation.8 To address this, the identity of 
fragment ion structures, corresponding to both variable and consistent m/z values, were found in 
the NIST MS Interpreter 2.0 (version 1.6/1.7/2.0). This hypothesis was confirmed with several 
ions, in which a variable m/z value corresponded to an ion which could be formed through 
multiple possible pathways but failed for other m/z values. The study presented here was not 
designed to address the link between fragmentation pathways and ion variation and it is beyond 
the scope of the author’s expertise. It is the author’s opinion that this phenomenon is worthy of 
investigation and a study should be designed to address the correlation of ion variation and 
fragmentation patterns/ability. 
3.4 Conclusions 
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Employing an independent tune check using DFTPP was not effective in reducing the 
variability observed in relative abundance values within- and between-days. Rather tuning 
frequency and tuning just prior to analysis was critical in minimizing this variation. Additionally, 
slight differences in tuning algorithms between vendors was noted and should be considered 
when comparing mass spectra. If an instrument is shown to be operating within laboratory 
defined acceptability criteria, frequent tuning is the best practice. When followed, regular tuning 
reduces the %RSD of relative abundances 5-fold compared to infrequent tuning. However, 
laboratories should appreciate that the intrinsic variation can be as high as 50% RSD, a factor 
that must be considered when structural identifications are made. 
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Chapter 4: Synthetic Small Molecule Characterization and Isomer 
Discrimination Using Gas-phase Hydrogen Deuterium Exchange 
Kelly, K.; Maleki, H.; Valentine, S.; Bell, S. Submitted for review to Analytical Chemistry. 
 
 
4.1 Introduction 
Novel psychoactive Substances (NPSs) describes various classes of small synthetic 
compounds designed to mimic the effects of specific illicit drugs. Although some analogues are 
currently regulated by agencies worldwide, slight side chain substitutions allow new analogs to 
evade regulations.1-2 The 1986 Anti-Drug Abuse Act in the United States was created to extend 
the drug legislation to analogues sold for human consumption.3 NPSs are commonly sold using a 
variety of marketing strategies to circumvent this amendment.1-2, 4-5 This combination of 
strategies has created an endless cycle where a new analog is readily available as a replacement 
once an existing analog is scheduled.4 The constant influx of new compounds has forced forensic 
laboratories to determine which NPSs are new analogs and which are already characterized. 
 Various detection methods have been employed for the analysis of NPSs in both seized 
materials and biological samples.1, 5 The current analytical trend is to utilize high-resolution mass 
spectrometry (HRMS) for proposed identity confirmation, by means of accurate mass, as well as 
structural elucidation by MS/MS.2 However, there are several drawbacks with this approach. 
First, this method is not capable of identifying regio-isomers. Secondly, interfaced 
chromatographic separation methods are often time consuming and do not provide unambiguous 
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identifications. One technique showing promise to overcome some of these drawbacks is ion 
mobility spectrometry (IMS) coupled to MS.6-11 IMS is currently employed as a presumptive 
screening test for illicit substances in high traffic locations, (i.e., mail depots, airports, border 
crossings, etc.).10 Despite its employment as a non-confirmatory technique in forensic 
applications, IMS-MS instrumentation is continually being developed and modified. These 
advancements have increased resolving power, improved the detection limits for components in 
complex mixtures, and helped improve structural inferences.6-7, 9, 12 Due to the complexity of 
isomer identification and the increased development of IMS and similar instrumentation, a 
paradigm shift is occurring where high-speed measurements related to different physiochemical 
property of compounds are bearing fruit.13-21 
 Solution-phase hydrogen deuterium exchange (HDX) has a rich history in the study of 
protein structure using MS techniques22-23 and is increasingly applied in the development of 
pharmaceuticals24-26; its usage for aiding in the identification of complex mixture components is 
relatively limited. Over the years, several have proposed using the mass-to-charge (m/z) shift of 
metabolites exposed to D2O as an indicator of the number of acidic hydrogens.
27-29 This 
measurement is used as a supplement to the measured precursor ion m/z values and 
chromatographic retentions times in order to reveal the identities of mixture components. More 
recently, gas-phase HDX has been used for biomolecule ion structure elucidation30-35 as well as 
to examine its potential for distinguishing metabolites in complex mixtures.36-38 Overall the gas 
phase approach offers advantages in measurement speed and reproducibility as well as offering 
significant potential for predicting the HDX behavior of compounds for which data have not 
been previously recorded. Notably, experiments have been performed for compounds containing 
a limited number of exchangeable hydrogens.37 More recently, compositional and linkage 
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isomers of oligosaccharides were distinguished using HDX despite these isomers not being 
resolved using IMS alone.38 To date, gas-phase HDX has not been applied to aid in the 
identification of NPSs. 
 This proof-of-concept study utilized gas-phase HDX-IMS-MS for the analysis of select 
NPSs (compound names and structures shown in Table C1) in the presence of two different 
reagent gases, D2O and ND3. Of the six initial NPSs analyzed for exchange propensity, one 
compound showed no exchange in the presence of either reagent gas. Four of the six NPSs 
showed efficient exchange in the presence of ND3 but little to no exchange in the presence of 
D2O. The only compound which showed exchange with both reagent gases was benzyl 
piperazine; it was hypothesized that the six-membered diamine ring facilitated exchange in the 
presence of D2O. Three disubstituted aromatic ring isomers (ortho-, meta-, and para- 
fluorophenyl piperazine), in which one substituent is a diamine ring, were then analyzed to 
determine if gas-phase HDX propensity could discriminate among the fluorophenyl piperazine 
isomers. It was shown that complete discrimination, with the current instrumentation, was 
possible at the α=0.05 level. Importantly, deuterium exchange of both reagent gases is required 
for complete isomer discrimination between ortho-, meta-, para-fluorophenyl piperazine. 
Molecular dynamics (MD) simulations provide insight into the underlying molecular behavior 
which is hypothesized to contribute to the deuterium exchange differences. 
4.2 Materials and Methods 
4.2.1 Chemicals and Reagents 
Deuterated ammonia (ND3) and water (D2O) was purchased from Sigma-Aldrich(St. 
Louis MO). LCMS grade methanol and Optima LCMS grade acetonitrile were obtained from 
Fisher Scientific (Fair Lawn NJ). Glacial acetic acid was obtained from EM Science (Gibbstown 
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NJ). NPS standards were purchased from Cerilliant (Round Rock TX) and Cayman Chemical 
(Ann Arbor MI). The six initial NPSs studied were prepared in standard solutions at 
concentrations of 10 ppm in 1:1 methanol:acetonitrile and 1% acetic acid. The three fluorophenyl 
piperazine isomer standards were at concentrations of 50 ppm in the same solvent proportions. 
Details regarding the concentration change are described in Section 4.2.3. 
4.2.2 Experimental Design 
The six initial NPSs were chosen based on potentially labile hydrogen atoms, specifically 
amine functional groups (Table 4.1). The fluorophenyl piperazine isomers were chosen because 
they contained a diamine ring, which was linked to the propensity of HDX in the presence of 
D2O. It is instructive to note that isomeric compounds selected for this study have been analyzed 
by GCMS. In these experiments, the retention times were nearly identical indicating the 
compounds could not be resolved by GC. 
4.2.3 Instrumentation 
The instrument used in this study has been described in detail previously.13, 36 A brief 
description of instrumentation is presented here, and an instrument schematic is provided as 
Figure C1. The instrument consists of a home-built drift tube coupled with an LTQ Velos linear 
ion trap (ThermoScientific, San Jose, CA, USA) mass spectrometer. Samples are infused at a rate 
of 300 nL/min via a pulled-tip capillary biased at +2000 V relative to the entrance of a 
differentially-pumped desolvation region. The ions are focused in an hour-glass ion funnel13 and 
temporarily stored in the first ion gate (G1) all contained within the desolvation region. The ions 
are periodically pulsed (~50 Hz) into the drift tube, which is filled with He buffer gas (~300 K 
and ~2.5 Torr) and supports a drift field of ~10 V∙cm-1. Differences in mobilities through the 
buffer gas cause ions to reach the second ion gate (G2) at different drift times (tD). All pressures 
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were monitored using a Baratron capacitance manometer (MKS, Andover, MA, USA). Drift time 
resolved mass spectra were created by applying a gating pulse to G2. The gating pulse was 
delayed with respect to the ion introduction pulse which set the tD of each mass spectrum. 
Because this study used analyte standard solutions rather than mixtures of analytes, the tD delays 
were scanned for the m/z of interest corresponding to the nominal mass of the ion. Mass spectra 
were collected at 0.2-ms step size intervals across the entire tD range of the peak (m/z) of interest. 
Intensities across the entire isotopic distribution were summed to provide tD-resolved intensities. 
All mass spectra (.RAW files) were converted into text files (.TXT), containing the m/z values 
and corresponding signal intensities, using the Xcalibur software suite (Version 2.2 SP1.48, 
ThermoScientific). The .TXT files were imported into Excel (Microsoft Cor., Redmond, WA, 
USA) for further analysis. 
Drift time values were recorded in duplicate using two different ion gating schemes. The 
first scheme positions G1 at the back of F1 (Figure C1). This traps ions in the hour glass funnel 
prior to injection in the drift tube. The second positions G1 further in the drift tube as shown in 
Figure C1. Here, G1 is a true Tyndall gate. The former scheme provides significantly higher 
signal levels (often required for HDX) while the latter is expected to provide a more accurate tD 
value due to the precisely defined and static electric field in the gating region. That is, it is 
difficult to determine the effect of the RF field on the ions as they exit F1 through the first gating 
configuration. Therefore, the usage of the Tyndall gate serves as a cross check of collisional 
cross section values (see below). Because the fluorophenyl piperazine isomers were analyzed 
solely on the latter scheme, the analyte concentrations were increased to reflect the lower signal 
intensities expected with the Tyndall gate. The initial six NPSs were analyzed first with the 
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gating scheme that provided higher signal levels, therefore solutions were made with a lower 
analyte concentration. 
4.2.4 Collisional Cross Section Calculation 
Experimental collisional cross sections (DTΩHe) were calculated using the following 
expression: 
DT𝛺𝐻𝑒 =
(18𝜋)
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               (eq. 4.1) 
where ze is the charge of the ion; E is the electric field strength; T is the temperature of the buffer 
gas; kb is Boltzmann’s constant; mi and mb are the masses of the ion and the buffer gas, 
respectively; L is the length of the drift tube; P is the pressure of the buffer gas; and N is the 
density of the buffer gas at STP. Because the tD window for small molecules is narrow relative to 
the instrument’s optimum sampling step size is (0.2 ms), under-sampling occurs at times for 
some high-mobility species. For all measurements, CCS values were calculated using the signal 
intensity weighted centroid of the distribution. 
4.2.5 Deuterium Uptake 
For HDX experiments, ~0.020 and ~0.040 Torr of the exchange gases, ND3 and D2O 
respectively were added to the He buffer gas system via evaporation through a variable leak 
valve. Once the leak valve was opened, data were not recorded until the system’s pressure 
stabilized to within ±0.005 Torr. For each mobility-selected compound the deuterium uptake 
level was determined for D2O and ND3 separately. Between replicate HDX measurements the 
reagent gas was removed and then reintroduced using the same leak valve settings. The number 
of deuterons incorporated into the molecule was determined by subtracting the average m/z 
values recorded in He only from the average m/z value after exchange. Similar to the weighted 
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average tD calculation, each isotopologue within a user defined m/z range was weighted by its 
corresponding intensity. 
4.2.6 Molecular Dynamics Simulations 
MD simulations were performed in triplicate on three disubstituted aromatic ring 
isomers:   ortho-, meta-, and para- fluorophenyl piperazine. The simulations required the 
construction of singly-charged molecules, topology files, and parameter files. The fluorophenyl 
piperazine isomers were constructed in Avogadro39 (Version 1.2). Each isomer has two potential 
protonation sites (Scheme 1). Although protonation is possible on either site, the more accessible 
nitrogen with the higher basicity, site 1 in Scheme 1, was chosen for protonation. The initial 
energy minimization was performed using the Amber force field FF96 within Avogadro. 
Because topology and parameter files for any of the fluorophenyl piperazine isomers have not 
been previously reported, these files were created using the CHARMM General Force Field 
(CGenFF) program. Here a mol2 file of the molecule is uploaded into the program interface40-41 
(Version 1.0.0). The program then performs atom typing, assigns partial atom charges, and 
provides parameters that includes the molecular force field42-43 (Version 3.0.1) for simulations. A 
psf file of the system of interest is generated using the topology files. Finally, all CHARMM 
parameter files, including the new CGenFF, are read into the simulation configuration files; the 
simulations were executed using NAMD44 (Version 2.12). A 20-ns simulation for each isomer 
was run in vacuo. A timestep of 0.5 fs was used saving molecular coordinate files every 2,000 
steps. Simulations were visualized and analyzed using VMD45 (Version 1.9.3) software. 
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Scheme 4.1a. Structure of ortho-fluorophenyl piperazine highlighting the two potential 
deuterium exchange sites. 
For simulations, the more basic site (site 1) was protonated. 
b)  
Scheme 4.1b. Example of the atoms labelled for calculation of the dihedral angle. 
 
The dihedral angle between the two ring structures was calculated and plotted for each 
molecular coordinate using VMD. Because all structures were constructed in the same format, 
the individual atom names in the psf files were identical. The atoms forming the dihedral angle 
(Scheme 1) were the C1, N1, C5, and C6 for all isomers, where the C6 atom is the carbon on the 
side of the aromatic ring where the fluorine is located for the various isomers. Dipole moments 
were calculated using the DipWatch plug-in (version 1.0) in VMD for the first simulation for 
each isomer. This plugin calculated the dipole moment for each molecular coordinate saved in 
the simulation; the dipole moment data were converted to .TXT files and imported to Excel for 
further analysis. 
CCS values were calculated using the trajectory method46 with the Mobcal software 
suite47 for every 100th structure in the first of the triplicate simulations for each isomer; this 
totaled 1,000 structures in which CCS values were calculated. The information contained in the 
original psf file was converted to a library (.lib) file. The coordinates of each sampled structure 
were saved as XYZ files (.XYZ) and then converted to an MFJ file format (.MFJ) using a custom 
76 
 
MATLAB script (Version R2018a) (The MathWorks, Inc., Natick, MA, USA). The MATLAB 
script was written for biological molecules and was not applicable to fluorine containing 
molecules. To address this, the atom mass of fluorine (18.9980) was changed in the .lib file to 
the mass of oxygen (15.9994). This allowed the MATLAB script to convert the .XYZ files to 
.MFJ treating the fluorine as an oxygen. Although not ideal, this conversion only affects the 
atomic radii (the atomic radii difference of oxygen compared to fluorine is only ~2 picometers)48 
and retains the partial charge associated with the fluorine parameters. The mean CCS value was 
compared to the experimental value for each isomer. 
4.3 Results and Discussion 
4.3.1 Collisional Cross Section 
The experimental parameters used for CCS calculations (Equation 4.1) are shown in 
Table C1. Notably, by changing the position of G1 (see above), the effective drift tube length 
changed from 0.99 m to 0.93 m between the first and second drift measurements, respectively, 
for the initial six NPSs. It was also observed that broader peaks were obtained when G1 was 
operated directly at the back of F1 than when G1 represents a true Tyndall gate. This may be due 
to the more precisely defined electric field in this region for the latter gating scheme which 
provides a more accurate drift time. Table 4.1 shows the ion CCS values for all compounds 
examined here. To our knowledge, none of the NPSs reported here have helium CCS values 
reported in the literature and few have been recorded for any drift gas. It is important to note that 
the CCS values of the three fluorophenyl piperazine isomers are nearly identical making them 
indistinguishable by IMS and MS alone. 
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Table 4.1.CCS values and deuterium uptake for all compounds. 
Compound1 
M.W. 
(g/mol) 
Amine 
Groups 
CCS 
(Ȧ2)2 
Deuterium Uptake3 
D2O ND3 
4-fluoroamphetamine 154 1° 68 (3) 0.09 (3.53E-2) 2.54 (7.36E-1) 
Benzyl piperazine 177 2°, 3° 76 (2) 1.07 (6.29E-2) 1.85 (2.01E-1) 
5-MeO-AMT 205 1°, 2° 82 (2) 0.15 (6.78E-2) 3.43 (4.48E-1) 
Methylone 208 2° 78 (2) 0.16 (3.46E-2) 1.84 (4.00E-2) 
AH-7921 329 2°, 3° 107 (4) 0.02 (1.07E-1) 0.30 (4.02E-2) 
25C-NBOMe 336 2° 112 (0) 0.02 (2.27E-2) 1.99 (3.96E-2) 
Ortho 181 2°, 3° 77 (1) 1.79 (4.80E-3) 1.90 (6.13E-2) 
Meta 181 2°, 3° 78 (0) 1.85 (1.15E-2) 1.89 (4.62E-3) 
Para 181 2°, 3° 77 (1) 1.85 (7.39E-3) 1.84 (4.14E-3) 
1The ortho, meta, and para indicate fluorophenyl piperazine isomers. 
2Differences in CCS values determined by the duplicate measurements are noted parenthetically. 
3Two Standard deviations, estimate of 95% confidence interval (n=3), are shown parenthetically. 
4.3.2 HDX Reactivities 
The exchange mechanisms of the reagent gases were examined in the 1990’s and it was 
suggested that exchange occurs via different mechanisms.49 Deuterium exchange with a D2O 
molecule occurs via the ‘relay mechanism’ in which the protonation site and an additional basic 
site on the analyte must be in close proximity for the transfer to occur. The proton from the 
charge site is transferred to the D2O molecule as a deuteron is shuttled to a less basic site on the 
analyte. Therefore, for the exchange to occur, a long-lived reaction complex must be formed near 
the exchange site. Conversely, exchange involving ND3 as the reagent molecule occurs via an ‘-
onium ion mechanism’. Simultaneously the deuterated reagent onium is solvated, and the 
deuteron is exchanged to the available site on the analyte. Comparatively, the onium ion 
exchange process is more efficient than the relay mechanism and is, thus, possibly less 
discriminate.49 
 An initial evaluation of the HDX propensity was conducted for six compounds (Table 
4.1 top) encompassing a variety of heteroatom sites that are potential sites of exchange (i.e. 
single or multiple amines and primary, secondary, and tertiary amines) and structural features 
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(i.e. amines within ring structures, terminal amines, etc.). Five of the six molecules showed 
minimal to no exchange when D2O was the reagent gas (Figures 4.1 and C2a-e). Methylone, for 
example, showed minimal deuterium uptake with D2O as evidenced by a slight increase in the 
abundance of the D1 and subsequent isotopologue peaks (Figure C2c). Five of the six molecules 
showed more significant exchange in the presence of ND3. Interestingly, 5-MeO-AMT contained 
four heteroatom hydrogens on two separate amine sites (Figure C2e); this compound showed 
significant ion populations undergoing three and four exchanges in the presence of ND3. 
Exchange on both amine sites suggests that exchange with ND3 is less discriminate, exchanging 
all possible labile heteroatom hydrogens. On the other hand, AH-7921 showed minimal 
exchange in the presence of either reagent gas (Figure Cd). AH-72921 contains both a tertiary 
amine and an amide; both groups are near bulky structures within the molecule which may 
reduce the accessibility of the reagent gas to the exchange site. The inability to exchange with 
ND3, despite ND3 being indiscriminate as a reagent gas (as evidenced by the exchange with 5-
MeO-AMT), suggests that this is case. Average deuterium uptake values and the estimation of 
the 95% confidence interval are reported for all mobility selected compounds in Table 4.1.  
Benzyl piperazine [M+H]+ ions were the only ions, of the initial 6 compounds, showing 
appreciable exchange with D2O (Figure 4.1). This is shown by the decreased abundance of the 
D0 isotopologue and the increased abundance of the D1 and D2 ions. Compared to ND3, exchange 
in the presence of D2O was less efficient as the D0 peak persists to a much greater extent. It was 
hypothesized that the unique diamine ring in the compound allows exchange in the presence of 
D2O. Because the nitrogen atoms are fixed in the ring structure, the proximity requirement of the 
site of protonation and the charged site is relatively ensured. Therefore, the diamine ring 
structure more likely favors the formation of the long-lived reaction complex. 
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Figure 4.1. Isotopic distributions for benzyl piperazine. 
For reference, the D0 and D2 isotopologue peaks are labeled and the protonated molecular 
structures are provided as insets. 
 
4.3.3 Discrimination of Disubstituted Aromatic Ring Isomers 
   The fluorophenyl piperazine isomers were chosen for this study because they contained 
the diamine ring enabling HDX with D2O and the standards were available in all three isomer 
positions (ortho-, meta-, and para-). When the isomers were in the presence of the drift gas (He), 
isotopic distributions are indiscernible, as shown in Figure C3. The analysis of each isomer after 
reacting with D2O and ND3 revealed small variations in the isotopic distributions indicating that 
there were slight differences in the deuterium uptake (Figures 4.2a and 4.2b). Because the 
relative abundance of the D1 ion peak for the ortho isomer during D2O analysis is larger (~25%) 
compared to the para isomer (~14%), it appears that these ions undergo fewer exchange events 
(Figure 4.2a). Indeed, the average deuterium uptake values are observed to be 1.79 and 1.85 for 
the ortho and para isomers, respectively (Table 4.1 bottom). Figure 4.2b shows that this is 
reversed for the D1 ion peak when ND3 is used as the reagent gas. On average, the ortho and para 
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isomers exhibit 1.90 and 1.84 deuterium uptake, respectively, when ND3 is used as the reagent 
gas (Table 4.1 bottom). Finally, it is noted that the use of ND3 results in greater exchange for 
many of the ions studied here. This may be expected as exchange with ND3 does not rely on the 
‘relay mechanism’.49 
It is also of interest to note the mass shift that occurs with the D1 ion peak for ortho 
isomer in the presence of both reagent gases and, to a lesser extent, with the meta ions in the 
presence of D2O (Figures 4.2a and 4.2b). These mass shifts have been known to occur with ion 
trap mass spectrometers for ions of with specific physiochemical properties, namely easily 
polarizable50 and permanent dipole moments51. The theoretical dipole moments of the three 
isomers were calculated (Table C2); all three fluorophenyl piperazine isomers studied have 
permanent dipole moments indicating the isomers are polarizable, albeit to different degrees. The 
ortho isomer has a smaller dipole moment compared to meta and para. The observed mass shift 
is thought to be the result of the permanent dipole moment and the polarizability differences of 
the isomers. 
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Figure 4.2a. Isotopic distributions for all fluorophenyl piperazine isomers when D2O is used as 
the reagent gas. 
 
  
Figure 4.2b. Isotopic distributions for all fluorophenyl piperazine isomers when ND3 is used as 
the reagent gas. 
 
With the deuterium uptake values, a question arises as to the utility in distinguishing the 
fluorophenyl piperazine isomers. As shown in Figure C3, the D2O deuterium uptake of the meta 
82 
 
and para isomers are nearly identical, as is the ND3 deuterium uptake for the ortho and meta 
isomers. Each sample measurement, i.e. each isomer with each reagent gas, was recorded in 
triplicate (n=3). A Tukey means comparison was performed using Origin (OriginLab, North 
Hampton, MA) at the α=0.05 level shows that the meta-para D2O comparison and the ortho-meta 
ND3 comparison are not significantly different (p=0.97 and p=0.87, respectively). All other 
comparison pairings for both D2O and ND3 are significantly different with p-values in the E-6 to 
E-2 range. In short, the data from individual reagent gases does not necessarily allow for the 
discrimination of the fluorophenyl piperazine isomers but the combined data provides complete 
isomer discrimination at the 95% confidence interval. Additional studies should be performed to 
ensure inter-instrumentation discrimination; however, the data presented here demonstrates the 
ability to confidently discriminate between isomers with the current experimental setup. 
The causes of the observed HDX differences when comparing reagent gases are difficult 
to elucidate. However, it was hypothesized that the substitution position on the aromatic ring 
within the fluorophenyl piperazine isomers could play a role in HDX kinetics. For exchange with 
D2O, for example, the electronegative fluorine atom at the ortho position would render the 
shuttle nitrogen less basic suggesting less facile initial deuterium incorporation. For the para and 
meta isomers, this effect could be somewhat diminished resulting in higher efficiency of initial 
deuterium incorporation. For HDX with ND3, the stabilization of the onium ion intermediate and 
closer proximity of the fluorine constituent for the ortho and meta isomers could lead to 
increased exchange for these ions. 
4.3.4 Molecular Dynamics Simulations 
Molecular dynamics (MD) simulations were performed to determine if deuterium uptake 
differences could be further elucidated in light of structural fluctuations. In general, the 
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theoretical CCS values were in good agreement with experimental values for all three 
fluorophenyl piperazine isomers (Table C2). The dihedral angle of each isomer, as defined in 
Scheme 1, was tracked for each replicate simulation (Figure 4.3). The meta and para isomer 
dihedral angles behaved somewhat as expected- angle populations at ± 0°, 60°, and 180°. The 
ortho isomer, conversely, shows that the dihedral angle favors <0°. The observance of values 
above 0° suggests that although it is possible for the two rings to rotate a full 360°, angles >0° 
are less favorable. This was observed for all 3 simulations (Figure C5a). Essentially the ring 
structures favored an orthogonal positioning to one another, creating a ‘limited angle’ for 
rotation. This appears to result from the close proximity of the fluorine to the diamine ring. 
 
Figure 4.3. Dihedral angle between the aromatic ring and diamine ring for all fluorophenyl 
piperazine isomers. 
The first simulation is shown for all isomers. The x-axis is time, i.e. where each isomer starts at 0 
ns and finishes at 20 ns. 
 
 
The reduced deuterium uptake from D2O of the ortho isomer, compared to the other 
isomers, may result from a hindrance to formation by this more rigid system. For example, the 
exchange complex formation may be destabilized on the side of the diamine ring in which the 
fluorine resides. The rigid system may also contribute to the larger error bars noted with the 
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ortho isomer in the presence of ND3.  This is in contrast to the meta and para isomers, where all 
naturally favored dihedral angles are sufficiently represented in the MD simulations signifying 
that these isomers experience a ‘free’ rotation between the ring systems. Such an explanation of 
rotation cannot be invoked for exchange by ND3, as the meta and para isomers exhibit different 
exchange levels. Rather, as mentioned above, the proximity of the fluorine may impart better 
stabilization of the onium ion complex for the former isomer. 
4.4 Conclusions 
Of the six NPSs initially evaluated for exchange propensity, one compound did not 
exchange with either reagent gas. It is hypothesized that the bulky structures surrounding the 
amine sites in AH-7921 reduce the accessibility of the reagent gas to the exchange site resulting 
in minimal exchange. Only one of the initial NPSs exchanged with both reagent gases, benzyl 
piperazine. The diamine ring of this NPS, and of the fluorophenyl piperazine isomers 
subsequently studied, provided a fixed length between the exchange site and the charge site. This 
likely facilitated the exchange with D2O, which, despite being less efficient than ND3, was 
capable of exchange with at least one labile heteroatom hydrogen. A NPS capable of exchange in 
the presence of D2O suggests that a fixed length/position, or nearly fixed position, between the 
exchange position and the additional charge site is present. Structural inferences like these, can 
aid in compound identification. 
  Despite selecting NPSs with potentially labile heteroatom hydrogens, five of the nine 
NPSs studied did not exchange with D2O. It is also important to note that NPSs without 
heteroatoms (which would not contain potentially labile hydrogens) have been identified. This 
novel application, however, demonstrates that discrimination is possible if the compound 
exchanges in the presence of both reagent gases. Even though IMS and MS is not capable of 
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distinguishing the ortho-, meta-, and para-fluorophenyl piperazine isomers here, HDX is capable 
of discrimination at a 95% confidence interval with the current instrumentation. These findings 
suggest gas-phase HDX can add a level of discrimination for non-targeted, small molecule 
analysis. 
Future work has several avenues of interest. Studies analyzing various piperazines, 
containing the diamine ring, with different halogens and/or substitutions will be pursued. This 
would identify if isomer discrimination with less electronegative substitutions is possible and 
will determine how substituents affect HDX on small synthetic molecules. As a final note, an 
inter-laboratory study should be conducted to evaluate HDX isomer discrimination among 
instruments and laboratories. 
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Chapter 5: Conclusions and Future Directions 
5.1 Conclusions 
 Forensic drug chemistry is facing a unique and challenging environment created by the 
never-ending cycle of NPSs entering the drug market. Without standards, drug chemists are 
performing non-target analyses more often and relying on mass spectral library searches for 
identifications. During an initial evaluation of the inherent variation in GCMS mass spectra, it 
was shown that without frequent tuning the variation can be substantial (≤250% RSD). An 
additional source of uncertainty in GCMS identifications can result from inconsistent base peaks 
either within or between instruments. Because the signal intensity in mass spectra are reported 
relative to the most abundant peak, an inconsistent base peak within the same instrument results 
in increased uncertainty of all %RAs while an inconsistent base peak between two instruments 
hinders mass spectral comparisons. Although employed for decades, passing the EPA’s DFTPP 
criteria was not correlated with reduced variation, rather tuning frequency was associated with a 
reduction in ion %RA variation. With frequent tuning, i.e. immediately prior to analysis, 
variation was reduced 5-fold. Finally, it was noted that variation in %RAs is not independent of 
fragmentation patterns; however, thorough evaluation of this dependence was not possible with 
the current data set. 
As a novel approach to non-target NPS analysis, HDX-IMS-MS was evaluated in a proof 
of concept study for the potential discrimination of isomers with minute structural differences. 
Ortho-, meta-, and para- fluorophenyl piperazine isomer discrimination was feasible at a 95% CI 
with the current instrumentation when the data from both reagent gases was considered. Despite 
selecting NPSs with potentially labile heteroatom hydrogens, five of the six NPSs did not 
exchange with D2O. A fixed length between the chargeable site and the exchange site was linked 
94 
 
to the ability to exchange with D2O; this observation suggests that non-targeted HDX analyses 
can allow for additional structural inferences. One NPS did not exchange in the presence of 
either reagent gas, AH-7921. Because both potential exchange sites are surrounded by bulky 
structures within the molecule, the lack of exchange in the presence of either reagent gas was 
likely due to inaccessible exchange sites. Although NPSs with potentially labile hydrogens were 
chosen for the study, the low exchange reactivity in the presence of either reagent gas is a clear 
limitation of the technique, as data from both reagent gases were required for isomer 
discrimination. 
5.2 Future Directions 
 Three primary areas of interest remain for the evaluation of GCMS uncertainty. First, it 
would useful to investigate the frequency with which a library search returns the correct 
identification and, when incorrect, how often the correct NPS family is identified. This could be 
studied by analyzing NPSs, both with and without structurally similar analogues, known to be in 
the mass spectral library and conducting non-targeted library searches. Varying the structural 
similarity of the analytes will help identify how closely the search algorithm returns the correct 
NPS family. It would also be prudent to analyze all databases relevant to forensic drug chemistry 
including NIST, SWGDRUG, and Wiley Mass Spectra Database of Designer Drugs. Second, 
because the uncertainty of ion %RAs was found to be dependent, to an unknown degree, on 
fragmentation, it is possible that utilizing EPA tuning criteria is not fit for purpose. This can be 
investigated by comparing the ion %RA variation of DFTPP/BFB to NPSs; if the variation is 
sufficiently different, it may suggest that this tune check compound is not suitable for limiting 
the variation of NPSs. A study identifying a more relevant and fit for purpose tune check 
compound could be performed with the aim of developing a tune check criterion specifically for 
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NPSs. Finally, compounds that produce the same m/z value but have different structural features 
should be analyzed as an initial step to evaluate the dependence of ion %RA variation on 
fragmentation patterns. This information is vital in order to calculate of the inherent uncertainty 
of GCMS analyses. 
Because the HDX-IMS-MS study was proof of concept, there are a few research avenues 
which could be pursued and should focus on further evaluating the utility of HDX for small 
molecule non-target analyses. The first avenue to be pursued should be an interlaboratory study 
of isomer discrimination. Although the current instrumentation was shown to be suitable for 
isomer discrimination, other instrumentation should also be evaluated. Next, various phenyl 
piperazines with other halogen substitutions should be studied. Less electronegative halogens 
will undoubtedly affect the exchange reactivities, therefore, isomer discrimination should be 
evaluated with a variety of substitutions. The sum of these studies will provide a thorough basis 
evaluating the utility of this technique for isomer discrimination.   
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Appendix A. 
Chapter 2: Evaluation of the Reproducibility and Repeatability of 
GCMS Retention Indices and Mass Spectra of Novel Psychoactive 
Substances  ̶  Supplemental Information 
 
Figure A1a. %RSD plotted as a function of mean %RA for all three instruments. 
 
 
 
Figure A1b. %RSD plotted as a function of mean %RA for instruments A and B. 
Data from instrument C was removed to highlight the exponential decay pattern elucidated. 
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Figure A2. Three-dimensional plot comparing m/z, mean %RA and %RSD. Boxed data points 
are outliers which were investigated. 
 
 
Figure A3. 3-dimensional wall projection. 
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Table A1. Descriptive statistics for RIs for all NPSs. 
The number of replicates for each system was: A (n=9), B (n=14), and C (n=6). 
System Mean Std. Dev. %RSD Upper 95% CI Lower 95% CI 
1-(3-chlorophenyl) piperazine 
A 1751.1 2.2 0.13 1749.4 1752.8 
B 1749.2 1.7 0.10 1748.3 1750.2 
C 1757.6 1.0 0.06 1756.5 1758.6 
2,5-dimethoxy-4-iodoamphetamine 
A 1939.4 1.3 0.07 1938.4 1940.4 
B 1922.0 1.9 0.10 1920.9 1923.1 
C 1944.2 1.1 0.05 1943.1 1945.3 
4-fluoroamphetamine 
A 1148.4 2.4 0.21 1146.6 1150.2 
B 1147.3 0.7 0.06 1146.9 1147.7 
C -- -- -- -- -- 
25C-NBOMe 
A 2009.4 6.0 0.30 2004.9 2014.0 
B 1999.0 2.2 0.11 1997.8 2000.3 
C 2013.6 1.3 0.07 2012.2 2015.0 
25I-NBOMe 
A 2620.9 3.3 0.13 2618.4 2623.5 
B 2600.2 3.2 0.12 2598.3 2602.0 
C 2631.3 1.7 0.06 2629.6 2633.1 
AH-7921 
A 2828.9 3.0 0.10 2826.6 2831.2 
B 2805.7 3.2 0.12 2803.9 2807.6 
C 2842.7 1.7 0.06 2841.0 2844.5 
Amphetamine 
A 2643.0 3.3 0.13 2640.5 2645.6 
B 2634.8 3.2 0.12 2633.0 2636.6 
C 2657.1 1.6 0.06 2655.5 2658.7 
Benzyl piperazine 
A 1137.1 1.2 0.11 1136.2 1138.0 
B 1135.7 0.8 0.07 1135.2 1136.1 
C -- -- -- -- -- 
Butylone 
A 1502.5 4.9 0.33 1498.7 1506.2 
B 1498.8 1.1 0.07 1498.1 1499.4 
C 1503.0 1.5 0.10 1501.4 1504.6 
N,N-Dimethyltryptamine 
A 1788.4 1.4 0.08 1787.3 1789.5 
B 1783.7 2.0 0.11 1782.6 1784.8 
C 1794.6 0.9 0.05 1793.6 1795.6 
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JWH-018 
A 1799.1 1.9 0.11 1797.7 1800.6 
B 1794.7 1.9 0.11 1793.6 1795.8 
C 1804.7 1.1 0.06 1803.6 1805.9 
Mephedrone 
A 3248.4 3.6 0.11 3245.7 3251.2 
B 3233.4 5.5 0.17 3230.2 3236.6 
C 3263.3 2.1 0.06 3261.1 3265.5 
Methylone 
A 1462.8 1.8 0.12 1461.4 1464.1 
B 1460.5 1.3 0.09 1459.7 1461.2 
C 1466.4 1.1 0.08 1465.2 1467.5 
UR-144 
A 1717.6 1.2 0.07 1716.7 1718.5 
B 1712.0 2.5 0.15 1710.6 1713.5 
C 1724.1 0.9 0.05 1723.1 1725.0 
 
 
Table A2. Descriptive statistics for five most abundant ions for select NPSs. 
The number of replicates for each system was: A (n=9), B (n=14), and C (n=6). 
Ion 
(m/z) 
System 
Mean 
RA 
Std. 
Dev. 
%RSD 
Lower 95% 
CI 
Upper 95% 
CI 
1-(3-chlorophenyl)piperazine 
156 
A 32.5 0.3 0.76 32.3 32.7 
B 35.0 2.1 5.96 33.8 36.2 
C 32.6 3.1 9.35 29.4 35.8 
196 
A 22.2 0.2 0.78 22.1 22.3 
B 23.4 2.3 9.67 22.1 24.7 
C 27.9 2.6 9.32 25.2 30.7 
56 
A 8.7 0.5 6.24 8.3 9.1 
B 13.3 1.3 10.05 12.5 14.1 
C 46.7 28 58.96 17.8 75.5 
138 
A 12.5 0.4 3.10 12.2 12.8 
B 15.9 2.0 12.70 14.8 17.1 
C 16.8 7.4 43.90 9.0 24.5 
111 
A 11.4 0.4 3.88 11.1 11.8 
B 13.4 1.9 13.84 12.4 14.5 
C 19.2 9.5 49.69 9.2 29.2 
2,5-dimethoxy-4-iodoamphetamine 
278 
A 55.7 3.6 6.53 52.9 58.5 
B 16.7 1.8 10.98 15.7 17.8 
C 12.5 5.7 45.53 6.5 18.5 
77 
A 9.2 0.6 6.54 8.7 9.6 
B 5.2 0.6 11.50 4.8 5.5 
C 3.4 0.8 21.85 2.6 4.2 
100 
 
91 
A 6.8 0.4 5.61 6.5 7.1 
B 3.8 0.5 13.32 3.5 4.1 
C 2.2 0.5 21.52 1.7 2.7 
263 
A 6.4 0.4 5.64 6.2 6.7 
B 2.4 0.4 17.70 2.2 2.7 
C 0.9 0.8 91.84 0.0 1.8 
42 
A 3.3 0.2 7.11 3.1 3.5 
B 2.7 0.4 15.91 2.4 2.9 
C 3.8 2.4 63.16 1.3 6.4 
25C-NBOMe 
150 
A 35.4 2.2 6.16 33.7 37.0 
B 42.7 6.1 14.37 39.2 46.3 
C 39.2 3.8 9.76 35.2 43.2 
91 
A 30.9 1.0 3.17 30.2 31.7 
B 34.6 3.8 10.84 32.4 36.7 
C 49.2 21 41.89 27.6 70.8 
122 
A 9.4 0.2 2.07 9.3 9.6 
B 9.1 0.5 5.36 8.8 9.4 
C 9.6 0.9 8.85 8.7 10.5 
77 
A 6.4 0.8 12.94 5.8 7.0 
B 6.9 0.9 12.43 6.4 7.4 
C 11.0 6.5 58.99 4.2 17.8 
65 
A 4.1 1.6 38.63 2.9 5.3 
B 6.3 0.8 12.21 5.8 6.7 
C 12.0 6.7 56.19 4.9 19.1 
Amphetamine 
91 
A 24.0 1.0 4.07 23.3 24.8 
B 15.6 1.2 7.62 14.9 16.2 
C 9.5 3.3 34.67 6.0 12.9 
65 
A 12.4 0.6 4.60 11.9 12.8 
B 7.9 0.4 5.17 7.6 8.1 
C 7.3 3.1 42.67 4.0 10.5 
42 
A 6.0 0.3 4.35 5.8 6.2 
B 5.1 0.4 7.08 4.9 5.3 
C 6.9 4.1 58.78 2.7 11.2 
51 
A 4.8 0.3 5.60 4.6 5.0 
B 3.2 0.3 8.39 3.1 3.4 
C 3.6 1.8 49.14 1.7 5.5 
63 
A 4.5 0.3 6.35 4.3 4.8 
B 3.1 0.4 11.92 2.9 3.3 
C 2.8 1.8 64.55 0.9 4.8 
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JWH-018 
341 
A 100.0 0.0 0.00 100.0 100.0 
B 91.3 10 10.99 85.5 97.1 
C 97.7 5.7 5.79 91.8 103.6 
284 
A 54.3 1.1 2.03 53.4 55.1 
B 77.9 7.9 10.18 73.3 82.5 
C 51.2 14 26.71 36.9 65.6 
214 
A 50.8 1.4 2.76 49.7 51.9 
B 87.4 13 14.43 80.1 94.6 
C 31.1 13 41.79 17.5 44.8 
127 
A 51.2 2.1 4.01 49.7 52.8 
B 94.5 8.8 9.30 89.5 99.6 
C 42.5 9.5 22.27 32.6 52.4 
324 
A 43.0 2.1 4.92 41.4 44.7 
B 54.0 7.9 14.60 49.5 58.6 
C 44.3 5.2 11.66 38.9 49.8 
5-MeO-AMT 
161 
A 100.0 0.0 0.00 100.0 100.0 
B 100.0 0.0 0.00 100.0 100.0 
C 42.5 18 41.19 24.1 60.9 
44 
A 48.6 5.3 10.83 44.5 52.6 
B 76.8 14 18.73 68.5 85.1 
C 100.0 0.0 0.00 100.0 100.0 
160 
A 49.6 1.6 3.13 48.4 50.8 
B 48.3 8.6 17.84 43.4 53.3 
C 19.1 6.4 33.27 12.4 25.8 
146 
A 24.2 0.7 2.86 23.6 24.7 
B 25.0 2.5 10.16 23.5 26.5 
C 9.6 4.2 43.78 5.2 14.0 
117 
A 17.8 0.9 4.80 17.2 18.5 
B 20.2 3.8 18.82 18.0 22.4 
C 12.2 3.8 31.38 8.2 16.3 
UR-144 
214 
A 100.0 0.0 0.00 100.0 100.0 
B 100.0 0.0 0.00 100.0 100.0 
C 92.6 18 19.56 73.6 111.6 
144 
A 22.6 0.5 1.97 22.2 22.9 
B 31.2 3.5 11.22 29.2 33.2 
C 24.4 3.4 14.04 20.8 28.0 
43 
A 7.4 0.6 8.25 6.9 7.9 
B 15.7 31 19.44 13.9 17.5 
C 52.2 30 56.84 21.1 83.3 
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296 
A 15.7 0.7 4.33 15.2 16.2 
B 19.9 7.4 37.12 15.6 24.1 
C 20.3 7.9 38.80 12.0 28.6 
41 
A 6.1 0.6 9.47 5.6 6.5 
B 12.4 3.8 30.76 10.2 14.6 
C 47.9 37 78.35 8.5 87.2 
 
 
Figure A4. 1-(3-chlorophenyl)piperazine mass spectra with box comparison charts of the top 
five ions. 
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Figure A5. 2,5-dimethoxy-4-iodoamphetamine mass spectra with box comparison charts of the 
top five ions. 
 
 
 
Figure A6. 25C-NBOMe mass spectra with box comparison charts of the top five ions. 
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Figure A7. UR-144 mass spectra with box comparison charts for top five most abundant ions. 
 
 
 
Figure A8. 5-MeO-AMT mass spectra with box comparison charts for top five most abundant 
ions. 
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Figure A9a. Chromatogram from Yellow mix. 
 
 
  
Figure A9b. Chromatogram from Red mix. 
 
  
Figure A9c. Chromatogram from Blue mix. 
 
The overall signal is low (~102 on all instruments), which is expected as the concentrations of 
individual compounds chosen was low. The overall width for 4-fluoroamphetamine and 
amphetamine was consistently wider than all other compounds; it is postulated that this widening 
was due to the compounds eluting near the solvent. Furthermore, these were the only peaks 
which showed a slight amount of tailing. All other compounds showed narrow and symmetrical 
106 
 
peaks. The compound concentrations were optimized so that the chromatogram peak was ~30% 
normalized; however, some peak heights varied and would occasionally be present below this 
threshold (see 5-MeO-AMT in yellow mix). 
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Appendix B. 
Chapter 3: The Effect of Mass Spectrometry Tuning Frequency and 
Criteria on Ion Relative Abundances of Cathinones and 
Cannabinoids  ̶  Supplemental Information 
 
Figure B1. %RSD plotted as a function of the mean RA from single day analysis sets from all 
NPSs and separated by instruments. 
(n=3 to 10 depends on the individual data point, i.e. the ion was recorded a minimum of 3 times 
in a single day). Instrument A markers are enlarged by 0.25pts to increase visibility of data 
points located behind instrument B data points. 
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Figure B2a. All recorded RAs for select ions from NEB. 
 
 
Figure B2b. All recorded RAs for select ions from JWH-200. 
 
  
Figure B2c. All recorded RAs for select ions from JWH-149. 
 
Note y-axis scale change. 
115 352
0
10
20
30
40
50
60
70
80
90
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
m/z Value
109 
 
 
 
Figure B3a. All recorded RAs for select ions from MeMABP. 
 
 
 
Figure B3b. All recorded RAs for select ions from JWH-116. 
 
 
  
Figure B3c. All recorded RAs for select ions from BB-22. 
 
Note y-axis scale change. n=3 to 10 depending how many times the ion was recorded each day. 
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Figure B4. Sample chromatogram for NPS solutions.  
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Appendix C.  
Chapter 4: Synthetic Small Molecule Characterization and Isomer 
Discrimination Using Gas-phase Hydrogen Deuterium Exchange 
IMS-MS  ̶  Supplemental Information 
 
Figure C1. Schematic of the home-build drift tube used. 
The desolvation region contains funnel 1 (F1) and gate 1 (G1) where the ions are focused and 
stored before entering the drift tube. Funnel 2 (F2) focuses the ion beams and the gating pulse at 
gate 2 (G2) is used to filter ions based on drift time. 
 
Table C1. Experimental parameters used for CCS calculations. 
Thick horizontal line separates the initial evaluation of HDX and the compounds used for isomer 
discrimination investigation. Additional parameters (abbreviations correspond to those defined in 
equation 1): T=296K, E=800V, and mb=4g/mol. 
Compound Structure 
M.W. 
(g/mol) 
Parameter Trial 1 Trial 2 
4-fluoroamphetamine 
 
154 
P (torr) 
L (m) 
tD (ms) 
2.63 
0.99 
4.95 
2.54 
0.93 
4.36 
Benzyl piperazine 
 
177 
P (torr) 
L (m) 
tD (ms) 
2.70 
0.99 
5.60 
2.54 
0.93 
4.80 
5-MeO-AMT 
 
205 
P (torr) 
L (m) 
tD (ms) 
2.69 
0.99 
6.06 
2.57 
0.93 
5.28 
Methylone 
 
208 
P (torr) 
L (m) 
tD (ms) 
2.67 
0.99 
5.80 
2.57 
0.93 
5.03 
AH-7921 
 
329 
P (torr) 
L (m) 
tD (ms) 
2.66 
0.99 
7.79 
2.57 
0.93 
6.84 
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25C-NBOMe 
 
336 
P (torr) 
L (m) 
tD (ms) 
2.58 
0.99 
8.02 
2.57 
0.93 
7.05 
Ortho-* 
 
181 
P (torr) 
L (m) 
tD (ms) 
2.54 
0.93 
4.77 
2.54 
0.93 
4.85 
Meta-* 
 
181 
P (torr) 
L (m) 
tD (ms) 
2.54 
0.93 
4.90 
2.54 
0.93 
4.88 
Para-* 
 
181 
P (torr) 
L (m) 
tD (ms) 
2.54 
0.93 
4.80 
2.54 
0.93 
4.89 
*Refers to fluorophenyl piperazine isomers 
 
 
 
 
 Figure C2a. Isotopic distribution for 25C-NBOMe. 
No deuterium uptake occurs in the presence of D2O. In the presence of ND3, ions exchanged 2 
hydrogens; the peak at m/z 340 is the chlorine isotopic peak and is not the result of additional 
deuterium exchange. 
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Figure C2b. Isotopic distribution for 4-fluoroamphetamine. 
There is no deuterium uptake with D2O, but a majority of ions exchanged 3 hydrogens in the 
presence of ND3. 
 
 
 
 
Figure C2c. Isotopic distributions for methylone. 
There is minimal deuterium uptake with D2O, but a majority of ions exchanged 2 hydrogens in 
the presence of ND3. 
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Figure C2d. Isotopic distributions for AH-7921. 
There is no deuterium uptake in the presence of D2O and minimal deuterium uptake in the 
presence of ND3, as evidenced by the increased m/z 330 abundance. The m/z 133 is the chlorine 
isotopic peak and is not the result of deuterium uptake. 
 
 
 
Figure C2e. Isotopic distributions for 5-MeO-AMT. 
For reference, the D0, D3, and D4 isotopologue peaks are labeled and the protonated molecular 
structures are provided as insets. 
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Figure C3. Isotopic distributions for all fluorophenyl piperazine isomers in buffer gas. 
No reagent gas is present. 
 
 
Table C2. Theoretical CCS mean and 95% confidence interval range and dipole moments for the 
three fluorophenyl piperazine isomers. 
These values are in good agreement with experimental CCSs reported. Theoretical dipole 
moments calculated for all saved coordinates in the first simulation for each isomer. 
 CCS Dipole Moment 
Isomer Mean (Ȧ2) 2σ Range (Ȧ2) Mean (Debye) 
Ortho 77 74-80 12.5 
Meta 78 75-81 15.1 
Para 78 75-81 16.0 
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Figure C4. Comparison of deuterium uptake for the fluorophenyl piperazine isomers. 
Error bars are two standard deviations. 
 
 
 
Figure C5a. Dihedral angle between the aromatic ring and the diamine ring for ortho-
fluorophenyl piperazine. 
Simulation triplicates shown. X-axis is time, where each simulation starts at 0 ns and ends at 20 
ns. 
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Figure C5b. Dihedral angle between the aromatic ring and the diamine ring for meta-
fluorophenyl piperazine. 
Simulation triplicates shown. X-axis is time, where each simulation starts at 0 ns and ends at 20 
ns. 
 
 
 
 
Figure C5a. Dihedral angle between the aromatic ring and the diamine ring for para-
fluorophenyl piperazine. 
Simulation triplicates shown. X-axis is time, where each simulation starts at 0 ns and ends at 20 
ns. 
